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ABSTRACT 
Knowledge-based planning (KBP) techniques have been shown to provide 
improvements in plan quality, consistency, and efficiency for advanced radiation 
therapies such as volumetric modulated arc therapy (VMAT). While the potential clinical 
benefits of KBP methods are generally well known, comparatively less is understood 
regarding the impact of using these systems on resulting plan complexity and pre-
treatment quality assurance (QA) measurements, especially for in-house KBP systems. 
Therefore, the overarching purpose of this work was to assess QA implications with 
using an in-house KBP system and explore data-driven methods for mitigating 
increased plan complexity and QA error rates without compromising dosimetric plan 
quality. Specifically, this study evaluated differences in dose, complexity, and QA 
outcomes between reference clinical plans and plans designed with a previously 
established in-house KBP system. Further, a machine learning model – trained and 
tested using a database of 500 previous VMAT treatment plans and QA measurements 
– was developed to predict VMAT QA measurements based on selected mechanical 
features of the plan. This model was deployed as a feedback mechanism within a 
heuristic optimization algorithm designed to modify plan parameters (identified by the 
machine learning model as important for accurately predicting QA outcomes) towards 
improving the predicted delivery accuracy of the plan. While KBP plans achieved 
average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001) in mean bladder and 
rectum dose compared to reference clinical plans across thirty-one prostate patients, 
significant (p < 0.05) increases in both complexity and QA measurement errors were 
observed. A support vector machine (SVM) was developed – using a database of 500 
 xv 
previous VMAT plans – to predict gamma passing rates (GPRs; 3%/3mm percent dose-
difference/distance-to-agreement with local normalization) based on selected 
complexity features. A QA-based optimization algorithm was devised by utilizing the 
SVM model to iteratively modify mechanical treatment features most commonly 
associated with suboptimal GPRs. The feasibility was evaluated on 13 prostate VMAT 
plans designed with an in-house KBP method. Using a maximum random leaf gap 
displacement setting of 3 mm, predicted GPRs increased by an average of 1.14 ± 
1.25% (p = 0.006) with minimal differences in dose and radiobiological metrics.
1 
1. INTRODUCTION 
1.1. BACKGROUND 
1.1.1. Radiation Therapy Treatment Delivery and Planning 
Radiation therapy or radiotherapy involves the treatment of disease with the use 
of high-energy radiation, which can take different forms such as x-rays, gamma rays, 
electrons, and protons. The primary disease treated with radiation therapy is cancer, 
with over half of all cancer patients receiving radiation therapy during the course of their 
care.1 Typically, a cancer treatment team – comprising of physicians, physicists, 
dosimetrists, therapists, and other healthcare professionals – works to plan, simulate, 
test, and deliver a course of radiation therapy with the goal of simultaneously 
maximizing cancer cell death and minimizing cell damage in surrounding healthy 
tissues. This is an intricate process, marked by a plethora of treatment variables and 
parameters that the treatment team must define in order to provide the patient with high-
quality radiotherapy. 
One of the first choices that must be made is how to deliver the prescription dose 
of radiation to the targeted disease. For photon radiotherapy, this dose can be delivered 
either from outside of the patient or from directly within the patient. These two treatment 
modalities are called external beam radiotherapy (EBRT) and brachytherapy. While 
brachytherapy can present dosimetric and efficiency gains in specific treatment sites, 
EBRT is the far more commonly used type of radiation therapy and will be the focus of 
this work.2,3 Today, most courses of EBRT are delivered via a medical electron linear 
accelerator (or LINAC), which generates a beam of Bremsstrahlung x-rays by 
bombarding a tungsten target with electrons accelerated through a large potential 
difference. These beams of x-rays are directed toward the patient and shaped 
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specifically to result in a dose distribution conforming to the target. Physical beam 
blocks – such as collimating jaws and thin multi-leaf collimators (MLCs) in the head of 
the LINAC or customized Cerrobend cutouts – can combine to shape the radiation 
beam as desired by the treatment team. These LINAC features, among others, have 
permitted the development of modern advanced radiotherapy delivery techniques. 
Intensity modulated radiotherapy (IMRT) is a class of EBRT techniques defined 
by the utilization of radiation fields with spatially varying fluence patterns. While 
requiring more sophisticated software and hardware specifications, IMRT has been 
shown to produce dose distributions with significantly improved target conformality, 
healthy tissue sparing,4-6 and overall patient outcomes compared to non-modulated 
delivery techniques (such as three dimensional conformal radiotherapy, or 3DCRT).7-9 
While there are several specific implementations of using intensity modulated radiation 
fields for treatment delivery, the two most common are fixed-gantry IMRT and 
volumetric modulated arc therapy (VMAT). Fixed-gantry IMRT deliveries typically 
employ five to seven fields of spatially varying fluence patterns of radiation spaced over 
discrete angles around the patient. On the other hand, VMAT treatments involve the 
continuous rotation of the LINAC gantry around the patient while delivering intensity-
modulated segments of radiation at varying dose rates.10 Although the literature is 
inconclusive regarding dosimetric superiority,11-16 the VMAT technique has been shown 
to significantly increase treatment efficiency compared to fixed-gantry IMRT.17-23 VMAT 
represents the latest technological advancement of rotational delivery techniques and 
has become routine in clinical practice. Its clinical prevalence has even led some to 
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debate whether its advantages will soon make conventional fixed-gantry IMRT 
obsolete.24 
In order to facilitate VMAT’s rise in clinical popularity, software innovations have 
been necessary to take advantage of the hardware advances that enable a radiotherapy 
delivery with modulated gantry rotation speeds, MLC positions, and dose rates. 
Treatment planning systems (TPSs) are computerized applications that provide a virtual 
environment for the treatment team to efficiently design and simulate a patient’s 
treatment. A TPS models the physical treatment delivery devices (i.e. LINACs) and 
provides an algorithm for calculating the radiation dose upon computed tomography 
images of the patient’s anatomy. The general process of designing and evaluating 
simulated treatments within such a system is referred to as treatment planning. 
Treatment plans for VMAT deliveries must define hundreds of machine 
parameters to instruct the LINAC control systems how to deliver the radiation for a given 
patient. These parameters – notably the gantry speed, MLC leaf positions and speeds, 
and dose rate – must be chosen in a way that combine to result in the desired dose 
distribution. For simpler, non-modulated delivery techniques such as 3DCRT, a 
“forward” planning technique is utilized whereby planning parameters are manually 
defined and refined iteratively until the plan becomes clinically acceptable. Whereas for 
more sophisticated delivery modalities like IMRT and VMAT, an “inverse” planning 
approach – whereby the planner specifies the required clinical endpoints for each 
patient after which an optimization algorithm searches for a feasible solution – is 
required to efficiently determine clinically acceptable treatment plans. 
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Modern TPSs are equipped with these inverse optimization algorithms for 
addressing the impractical challenge of manually defining those mechanical parameters 
prior to dose calculation. As mentioned previously, the planner instead specifies arc 
angles, target dose goals, and dose goals for sparing surrounding organs at risk (OARs) 
so that an algorithm can heuristically search for a suitable set of intensity patterns and 
mechanical specifications that achieve the stated dosimetric goals.25 If a planner wants 
to improve the plan or assess clinical trade-offs, they must adjust the initial dosimetric 
objectives and weights and run another optimization round followed by dose 
computation. Represented as a numerical cost function to be minimized internally by the 
TPS, deterministic and stochastic optimization methods are typically combined to 
maximize the likelihood of finding a global – as opposed to local – minimum. However, 
the existence of these sophisticated inverse planning algorithms still does not guarantee 
a perfect or even clinically acceptable solution.25 
Chief among the many factors limiting a planner’s ability to arrive at the best 
treatment plan every time is the unique anatomy of each patient. Traditional planning 
techniques do not provide planners any a priori information regarding what parameters 
would result in the optimal plan for each patient. This limitation, along with the trial-and-
error nature of inverse planning, causes the quality of inversely optimized plans to be 
susceptible to planner bias, time constraints, and subjectivity. As a result, investigators 
have observed numerous instances of variation in inverse treatment plan quality.26-31 
Specifically, Nelms et al. found a wide variation in plan quality (defined in the study as 
the ability of planners and plans to meet specified goals) among different treatment 
planners and institutions.30 Interestingly, this finding was not statistically dependent on 
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technologic parameters such as TPS and modality (i.e. fixed-gantry IMRT versus 
VMAT) nor on planner demographics such as years of experience, certification, and 
education. Although, Batumalai et al. found more experienced planners produced higher 
quality head-and-neck IMRT plans.27 The authors instead suggest attributing the 
variation in plan quality to planner “skill,” an undefined and potentially unquantifiable 
term that underscores how inverse treatment planning can sometimes be more art than 
science. To this end, researchers began investigating techniques for mitigating these 
known deficiencies in traditional inverse planning. 
1.1.2. Knowledge-Based Planning 
One such area of research is knowledge-based planning, or KBP. Although there 
are many different categories and specific implementations, KBP systems generally 
leverage retrospective anatomical and dosimetric patient data to guide the planning of 
new patients. These data-driven approaches have been shown to improve the quality, 
consistency, and efficiency of IMRT and VMAT planning compared to traditional 
planning methods.32 Ge and Wu recently published a review article on KBP systems for 
IMRT where they classified the different types of KBP implementations into six 
categories based on the specific variables the models are designed to predict: (1) the 
entire dose-volume histogram (DVH),33-64 (2) one or more dose metrics,45,65-75 (3) voxel-
level dose,76-88 (4) objective function weights,45,89 (5) beam-related parameters (e.g. 
number of beams, beam angles, and jaw settings),90-94 and (6) quality assurance (QA) 
metrics.95-101 These specific categories can further be stratified into two major classes 
according to their underlying mechanisms: (A) case or atlas-based methods and (B) 
statistical modeling and machine learning methods. 
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Whereas KBP methods in class (B) form predictive models (e.g. regression and 
machine learning models) from an established database of previous patients, methods 
in class (A) query the database for matches or “similar” cases and transfer selected 
data to the new case. One such case-based technique was one of the first KBP 
implementations investigated due primarily to its robustness and simple clinical 
implementation. A seminal method was originally developed by Wu et al., where an 
anatomical similarity metric is used to query a database of previous patients to predict 
achievable dose-volume histogram objectives in IMRT planning.65 Specifically, the 
similarity metric used to quantify patient anatomy is the overlap-volume histogram 
(OVH). 
The OVH, introduced by Kazhdan et al., is a shape relationship descriptor that 
defines the distance at which fractional volumes of OARs lie from the target’s surface.102 
More specifically, it is defined for a target T and organ O, where the value of the OVH of 
O with respect to T at distance r is defined as the fractional organ volume a distance of r 
or less from the target: 
 "#$!,#(&) = |{+ ∈ "|-(+, /) ≤ &}||"|   
where d(p,T) is the signed distance of a point p from the target’s boundary and |O| is the 
volume of the OAR. An in-field OVH can be defined similarly for a structure O’, or the 
portion of the organ O within the treatment fields. Such in-field volumes can be 
estimated only considering voxels lying between the transverse planes 6 mm superior 
and inferior to the most superior and inferior aspects of the planning target volume 
(PTV) respectively (approximating the beam penumbra at depth). The in-field OVH has 
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been found to produce improved bladder and rectum dose prediction accuracy for 
VMAT prostate plans.103,104 
As mentioned previously, the clinical viability of OVH-driven KBP methods has 
been investigated due to the OVH’s robustness and its simple implementation.65,66,68,105 
All of these methods assume that the dose received by a fractional OAR volume 
depends on its proximity to the PTV, which is quantified by the OVH. Therefore, each 
point of an OAR’s OVH can be mapped to one point of the corresponding DVH, 
establishing a one-to-one relationship for each OAR of a given patient (Figure 1.1). This 
one-to-one distance-to-dose mapping can be formed by relating a distance rv of an OVH 
for a fractional OAR volume v to a dose-volume Dv of a DVH. This is the fundamental 
principle for how the OVH is used to predict achievable DVH dose metrics. 
 
Figure 1.1. Graphic (adapted from Wu et al.) illustrating how the OVH is defined for two 
example OARs and one PTV (left). It also shows the one-to-one relationship between 
an OAR fractional volume’s distance from the target (OVH) and the dose it receives 
(DVH), which is how OVHs are used to quantify patient anatomy for KBP dose-volume 
prediction.105 
Regardless of specific implementation, KBP methods have been observed to 
contribute to overall improvements in OAR sparing and planning efficiency for several 
treatment sites. For example, in Ge and Wu’s review of KBP approaches for prostate 
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cancer, they found a mean reduction in bladder and rectum dose of 2.0 and 2.6 Gy, 
respectively, across four different studies.32,51,55,59,103 Nevertheless, while reports of 
these KBP methods leading to improved plan quality and planning efficiency are 
encouraging, it is important to consider and investigate whether any clinical tradeoffs 
arise incidental to these positive results. 
1.1.3. Plan Complexity 
One potential consequence of improved plan quality is an increase in plan 
complexity. As alluded to in Chapter 1.1.1, IMRT and VMAT have become the preferred 
treatment delivery techniques for EBRT due to improved dose conformity to diseased 
tissue and sparing of surrounding healthy tissue compared to traditional 3DCRT. 
However, these techniques often result in increased beam modulation (i.e. complexity), 
which has previously been described by the changes in MLC leaf positions, the number 
of monitor units (MUs), the dosimetric uncertainty owing to losses in charged particle 
equilibrium caused by smaller beam apertures, and the susceptibility to interplay 
between the motions of the linear accelerator and internal organs.106-109 
IMRT and VMAT plans require combinations of many irregularly shaped and 
oftentimes small beam segments to obtain this increased dose conformity to target and 
sparing of OARs. Small beam segments have higher degrees of dosimetric uncertainty 
compared to traditional radiotherapies. This is primarily due to nonequilibrium conditions 
created by secondary electron track lengths and source sizes being comparable to 
small treatment field sizes, which results in increased beam penumbra.110 This 
uncertainty places an emphasis on the TPS’s ability to accurately model lateral electron 
scatter, MLC leaf ends, leaf transmission, and interleaf leakage for these plans. Among 
several sources of error, plan complexity has been linked to the deliverability of IMRT 
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and VMAT plans, with increased complexity often leading to decreases in quality 
assurance outcomes.111-113 Therefore, quantifying and reducing IMRT/VMAT plan 
complexity is a reasonable strategy to improve deliverability. 
Many different metrics have been established to quantify and describe plan 
complexity. Simple characteristic plan parameters such as total MUs give quick first-
order indications about a plan’s complexity. But other metrics are typically classified as 
fluence-based or aperture-based. More details on the complexity metrics used in this 
work can be found in Appendix D. 
1.1.4. VMAT Quality Assurance 
While VMAT is commonly available on modern commercial LINACs, the accurate 
delivery of this sophisticated treatment technique requires precise synchronization of 
MLC motion, gantry motion, and dose rate variations. Additionally, since continuous 
VMAT arcs are approximated by many discrete segments (or static beams) during the 
planning process, the delivery accuracy of VMAT treatments may depend on the 
discretization resolution and plan complexity.114 This increase in plan complexity 
(relative to non-modulated delivery techniques) underscores the clinical importance of 
the QA process, which ensures IMRT treatment plans can be delivered as intended and 
verifies the accuracy of the TPS dose computation. The current standard for VMAT QA 
is to measure the planned radiation fields with a physical measurement device, and to 
compare the result with that computed by the TPS. 
This is typically done by copying the approved plan from the patient’s geometry 
onto a water- or tissue-equivalent phantom with known specifications, upon which the 
dose is then recomputed within the TPS. The plan is delivered to the QA phantom, 
which contains one or more radiation detectors (typically diodes or ionization chambers) 
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to measure the dose (Figure 1.2). The agreement between the measured and 
calculated dose is then evaluated, after which the plan is either approved for treatment 
or rejected depending on the institution’s passing criteria. 
 
Figure 1.2. This shows the typical setup for VMAT QA at our institution, where the 
LINAC delivers the approved treatment plan to a known measurement device placed on 
the couch. 
Gamma analysis is one of the most prevalent methods utilized for comparing 
computed and measured dose distributions in VMAT QA. Introduced by Low et al., the 
gamma index is used to quantify both the percent dose-difference (%DD) and distance-
to-agreement (DTA) between two dose distributions.115 Specifically, the gamma index g 
is defined as, 
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 Γ(&$33⃗ 	, &%33⃗ 	) = 6&&(&$33⃗ 	, &%33⃗ 	)∆-& + 9&(&$33⃗ 	, &%33⃗ 	)∆:&   
 ;(&%33⃗ ) = min{Γ(&$33⃗ 	, &%33⃗ 	)}∀{&$33⃗ 	}  
where &(&$33⃗ 	, &%33⃗ 	) is the distance between the reference and evaluated points, 9(&$33⃗ 	, &%33⃗ 	) is 
the dose difference, and ∆- and ∆: are the selected DTA and percent dose-difference 
criteria respectively. g values equal to or less than one indicate that the comparison 
passed with respect to the selected %DD and DTA gamma criteria, whereas values 
greater than one indicate failure. The percent of points passing a given gamma criteria 
is typically referred to as the gamma passing rate (GPR) and is commonly used as a 
metric for quantifying the level of agreement between two dose distributions. Due to the 
complex nature of IMRT treatments, this QA assessment is needed to check for error-
free data transfer, the accuracy of the TPS dose calculations, and the deliverability of 
the plan on the treatment machine.114 Though there have been investigations into 
software-based QA protocols,116-118 measurement-based techniques are still considered 
the standard for QA. 
A consequence of increased plan complexity is the potential for reducing the 
accuracy of the delivered treatment, whereby the impact of uncertainties in relevant 
delivery parameters – such as MLC leaf positions – are exacerbated by small, 
irregularly shaped beam apertures and narrow leaf gap widths called for by the 
treatment plan. For instance, Masi et al. found that increased VMAT plan complexity 
(described by modulation complexity scores, or MCS, and leaf travel) was significantly 
correlated with lower quality assurance outcomes.113 This reduced treatment delivery 
accuracy can have clinical implications.113,119 These consequences have led 
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investigators to explore strategies for quantifying and reducing plan complexity without 
compromising plan quality.112,120,121 
1.1.4.1. Machine Learning for Patient-Specific Quality Assurance 
Several investigators have applied machine learning models for predicting QA 
outcomes based on treatment plan characteristics of fixed-gantry IMRT. Valdes et al. 
were able to predict GPRs within 3% accuracy for IMRT plans using a generalized 
Poisson regression model with Lasso regularization trained on a selection of 78 plan 
complexity features.95,96 Interian et al. developed an ensemble of convolutional neural 
networks trained to predict IMRT gamma passing rates from fluence maps with results 
comparable to the Poisson regression model.97 More recently, Lam et al. used tree-
based machine learning algorithms to predict GPRs for portal dosimetry-based IMRT 
beams with a mean absolute error of less than 1%.99 Such models can provide a priori 
information regarding the deliverability of plans during the optimization stage, which 
could provide many benefits that include minimizing wasted time in measuring and 
adjusting treatment plans that are likely to fail QA. 
While machine learning techniques have been primarily applied to fixed-gantry 
IMRT QA, an evaluation of applying similar techniques for VMAT QA represents a 
logical next progression. Granville et al. showed the feasibility of using machine learning 
to classify results of VMAT QA measurements, where they trained a support vector 
machine classifier to predict whether median dose differences between measured and 
planned dose distributions were ‘hot’ (deviation more than 1%), ‘cold’ (deviation less 
than -1%), or ‘normal’ (deviation within ±1%).122 Ono et al. used machine learning 
models to predict GPRs on a specific QA measurement device using plan complexity 
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features.101 These previous works show the feasibility of using machine learning 
algorithms to accurately predict QA outcomes. 
1.2. MOTIVATION FOR RESEARCH 
While the advantages of KBP techniques in treatment planning have been widely 
described, the impact of their use on plan complexity and deliverability are less well 
understood. Comparatively few studies have even reported on simple complexity 
surrogates of KBP plans. Hussein et al. found no significant changes in MU and MCS 
values of prostate IMRT plans when using a commercial KBP system (RapidPlan, 
Varian Medical Systems, Palo Alto, CA).49 Likewise, Tamura et al. found no significant 
changes in patient-specific quality assurance outcomes when using this commercial 
KBP system.123 Conversely, Kubo et al. reported significantly increased MU values and 
higher plan complexity when using the same commercial KBP system as the studies 
noted previously.124 These results suggest that further assessment of the complexity 
and deliverability of KBP-guided plans is needed. Therefore, the first purpose of this 
study was to examine differences in dose, complexity, and quality assurance outcomes 
between reference clinical plans and plans designed with an in-house KBP system. 
Another objective of this work is to build upon existing literature for implementing 
machine learning models for predicting VMAT QA outcomes. As mentioned in Chapter 
1.1.4.1, previous investigators have shown this application of machine learning 
algorithms to be feasible. However, each machine learning model is dependent on the 
characteristics of the available data. In this particular application of machine learning, 
each QA predictive model depends on the combination of technologies, the choice of 
machine learning model, and clinical protocols used for optimizing VMAT treatment 
plans, which can each vary across institutions. Therefore, the second purpose of this 
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work was to assess the feasibility of developing machine learning models for predicting 
VMAT GPRs at our institution, which utilizes a different combination of technologies 
(e.g. TPSs, delivery machines, and measurement devices) than previous works. 
Further, another aim of this work is to explore and assess different machine learning 
regression algorithms trained to predict gamma passing rates for VMAT QA from 
treatment planning parameters and metrics. 
Current TPSs have simple penalties to globally reduce complexity and for 
controlling the likelihood of a plan failing VMAT QA. For example, the RayStation TPS 
(v4.5.1.14; RaySearch Laboratories, Stockholm, Sweden) has one option to constrain 
MLC leaf motion to a limited distance per degree of gantry rotation. Other works have 
explored integrating other aperture-based penalties during optimization, where Younge 
et al. were able to reduce complexity without degrading dose.112 However, these 
penalties for reducing complexity do not guarantee a corresponding improvement in QA 
outcomes given their moderate correlation; any potential impact on QA outcomes would 
also be unknown until measurement. Investigators have consequently explored 
methods – like machine learning – for predicting delivery accuracy for purposes of 
identifying plans likely to fail QA prior to measurement. While these predictive models 
may save time by flagging those at-risk plans, they are limited to the post-planning 
stage. It would be ideal to actively optimize the treatment plans in terms of both dose- 
and QA-based metrics. To our knowledge, such an optimization workflow has not been 
investigated. Therefore, the third purpose of this work was to explore the feasibility of a 
planning QA tool that directly optimizes QA outcomes without compromising plan 
quality. 
 15 
1.3. HYPOTHESES AND SPECIFIC AIMS 
To this end, we hypothesized that KBP-guided plans result in significantly higher 
complexity and reduced gamma passing rates (p < 0.05) compared to reference clinical 
plans. Additionally, we hypothesize that a machine learning model designed to predict 
VMAT QA gamma passing rates can be used in plan optimization to increase predicted 
delivery accuracy without compromising KBP plan quality. In order to test these 
hypotheses, three specific aims were developed for this study: 
Aim 1. Evaluate differences in plan complexity and delivery accuracy between 
KBP and reference clinical plans of prostate cancer patients treated with 
VMAT. Use four common metrics to describe overall plan complexity for 
the VMAT plans and perform QA measurements to quantify differences in 
delivery accuracy between the two sets of plans. 
Aim 2. Develop, test, and compare different machine learning models for 
predicting gamma passing rates of VMAT QA measurements. Collect a 
large set of plan data to train and test the models for establishing 
performance. 
Aim 3. Develop and establish the feasibility of a planning QA tool. Deploy the 
model from Aim 2 to interact with a commercial TPS to provide feedback 
regarding the predicted QA outcome of the treatment plan during plan 
optimization. Develop an in-house optimization algorithm to maximize 
predicted delivery accuracy of inversely optimized treatment plans. 
Demonstrate proof-of-concept on selected KBP plans.  
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1.4. OVERVIEW OF DISSERTATION 
This document follows a manuscript-style dissertation format, where the main 
chapters contain content derived from papers already published in or in preparation for 
submission to peer-reviewed scientific journals. Below is a summary of these works and 
their main contributions to the literature. 
1.4.1. Chapter 2: Evaluation of complexity and deliverability of prostate cancer 
treatment plans designed with a knowledge-based VMAT planning technique 
This chapter concerns the assessment of dosimetric, mechanical, and delivery 
properties of plans designed with a common KBP method for prostate cases treated via 
VMAT. Thirty-one prostate patients previously treated with VMAT were re-planned with 
an in-house KBP method based on the overlap-volume histogram. VMAT plan 
complexities of the KBP plans and the reference clinical plans were quantified via 
monitor units, modulation complexity scores, the edge metric, and average leaf motion 
per degree of gantry rotation. Each set of plans was delivered to the same diode-array 
and agreement between computed and measured dose distributions was evaluated 
using the gamma index. Varying percent dose-difference (1% to 3%) and distance-to-
agreement (1 mm to 3 mm) thresholds were assessed for gamma analyses. KBP plans 
achieved average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001) in mean 
bladder and rectum dose compared to reference plans, while maintaining clinically 
acceptable target dose. However, KBP plans were significantly more complex than 
reference plans in each evaluated metric (p < 0.001). KBP plans also showed significant 
reductions (p < 0.05) in gamma passing rates at each evaluated criterion compared to 
reference plans. While KBP plans had significantly reduced bladder and rectum dose, 
they were significantly more complex and had significantly worse quality assurance 
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outcomes than reference plans. These results suggest caution should be taken when 
implementing an in-house KBP technique. 
1.4.2. Chapter 3: Application and comparison of machine learning models for 
predicting quality assurance outcomes in radiation therapy treatment planning 
This chapter describes the development and evaluation of machine learning 
models for predicting QA outcomes of VMAT treatment plans. A dataset of 500 VMAT 
treatment plans and diode-array QA measurements were collected for this study. GPRs 
were computed using a 3%/3mm percent dose-difference and distance-to-agreement 
gamma criterion with local normalization. 241 complexity metrics and plan parameters 
were extracted from each treatment plan and their relative importance for accurately 
predicting GPRs was assessed and compared using feature selection methods via 
forests of Extra-Trees, mutual information, and linear regression. Hyperparameters of 
different machine learning models – which included linear models, support vector 
machines (SVMs), tree-based models, and neural networks – were tuned using cross-
validation on the training data (80%/20% training/testing split). Features were weakly 
correlated with GPRs, with the small aperture score (SAS) at 50 mm having the largest 
absolute Pearson correlation coefficient (0.38; p < 0.001). The SVM model, trained 
using the 100 most important features selected using the linear regression method, 
gave the lowest cross-validation testing mean absolute error of 3.75%. This represents 
a significant 41.1% improvement (p < 0.001) over “random guessing” error as simulated 
by randomly sampling a fitted normal distribution to the testing data. These predictive 
models can help guide the plan optimization process to avoid solutions which are likely 
to result in lower GPRs during QA. 
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1.4.3. Chapter 4: Use of machine learning algorithm during optimization to improve 
patient-specific quality assurance in volumetric modulated arc therapy plans 
This chapter assesses the feasibility of optimizing plan deliverability of VMAT 
treatment plans using a machine learning model to predict QA outcomes. Current 
inverse planning algorithms incorporate specific mechanical restrictions – such as 
constraining leaf motion – that are designed to reduce the complexity of the treatment 
plan. However, mechanical constraints do not guarantee a corresponding improvement 
in measured QA outcomes. Therefore, this work explored the feasibility of an 
optimization framework for directly maximizing predicted QA outcomes of plans without 
compromising dosimetric quality. VMAT plans were retrospectively designed for 13 
prostate patients using a previously established in-house KBP method. An SVM was 
developed – using a database of 500 previous VMAT plans – to predict GPRs (3%/3mm 
percent dose-difference/distance-to-agreement with local normalization) based on 
selected complexity features. An optimization algorithm was devised by utilizing the 
SVM model to iteratively modify mechanical treatment features most commonly 
associated with suboptimal GPRs. Specifically, leaf gaps (LGs) less than 5 cm were 
widened by random amounts, which impacts all aperture-based complexity features 
such as small aperture scores and aperture area uniformity. The original 13 VMAT 
plans were optimized with this QA-based algorithm using maximum LG displacements 
of 1, 3, and 5 mm before corresponding changes in predicted GPRs and dose were 
assessed. Predicted GPRs increased by an average of 0.30 ± 1.22% (p = 0.42), 1.14 ± 
1.25% (p = 0.006), and 1.52 ± 1.27% (p =0.003) after QA-based optimization for 1, 3, 
and 5 mm maximum random LG displacements, respectively. Differences in dose were 
minimal, resulting in negligible changes in tumor control probability (maximum increase 
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= 0.05%) and normal tissue complication probability (maximum decrease = 0.22% 
among bladder, rectum, and femoral heads). A novel framework for optimizing predicted 
GPRs was developed and shown to increase predicted QA outcomes without degrading 
dosimetric quality of given plans. This method for integrating QA outcomes directly into 
planning optimization could help improve the probability and efficiency of arriving at a 
truly optimal treatment in terms of both dosimetric quality and QA outcomes. 
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2. EVALUATION OF COMPLEXITY AND DELIVERABILITY OF 
PROSTATE CANCER TREATMENT PLANS DESIGNED WITH A 
KNOWLEDGE-BASED VMAT PLANNING TECHNIQUE 
2.1. PURPOSE 
The purpose of this study was to evaluate differences in complexity and QA 
outcomes between reference clinical VMAT plans for prostate cancer and those 
designed with an in-house KBP method. 
2.2. MATERIALS AND METHODS 
2.2.1. Treatment Plans 
A total of 31 prostate cancer patients previously treated at our institution were 
used for the treatment planning in this study. Selected patients were originally 
prescribed a dose to a single PTV and treated using two coplanar, 6 MV VMAT arcs. 
The clinical plans were originally created using the current TPS at our institution 
(Pinnacle3 v9.10, Philips Medical Systems, Fitchburg, WI, USA). For research purposes, 
reference clinical plans were transferred or reconstructed in a research TPS 
(RayStation v4.5.1.14, RaySearch Laboratories, Stockholm, Sweden), where our in-
house KBP method was developed. These reference clinical plans were re-computed or 
re-optimized to approximate the original clinical plans (see Figure C.1 in Appendix C.1). 
In addition to these reference clinical plans, a KBP-guided plan was generated 
for each of the 31 patients using an in-house KBP technique. The KBP method, based 
on OVHs incorporating fractional OAR volumes only within the treatment fields,was 
 
Contents of this chapter were previously published as Wall PDH, Fontenot JD. Evaluation of complexity 
and deliverability of prostate cancer treatment plans designed with a knowledge-based VMAT planning 
technique. J Appl Clin Med Phys. 2020;21(1):69-77. Reprinted by permission of Wiley Periodicals, Inc. 
(Appendix B.1) 
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used to generate patient-specific bladder and rectum dose-volume predictions at the 
10%, 30%, 50%, 65%, and 80% relative volume levels. These dose-volume predictions 
were then input to the TPS as planning objectives and a KBP-guided plan was 
optimized for each patient. Additional details of our KBP method are described 
elsewhere103,125, but this OVH-guided KBP method was used in this study because it 
can be easily implemented clinically and it has been previously shown to predict 
achievable OAR dose-volumes.65,68,126 Moreover, it is useful to investigate these types 
of in-house KBP systems for clinics that may not have the resources or ability to acquire 
commercially available KBP systems. 
A unique feature of this KBP method is that in addition to the manually-
constructed clinical plans, the dose database was also populated with standardized 
Pareto-optimal plans that equally weighted sparing of each OAR. When a dose-volume 
was queried for patients with similar in-field OVHs to the new patient, the lowest dose 
value among both the clinical and Pareto plans was selected as the new patient’s 
predicted dose-volume. Our previous work showed the knowledge from the Pareto 
plans often resulted in better achievable dose predictions.125 So it is important to 
emphasize that the predicted dose-volume objectives from this KBP technique are 
selected from the lowest dose values among the clinical and Pareto plans available in 
the database. 
It is also important to note that the KBP system is separate from the TPS 
optimization engine, whereby the KBP algorithm predicts dose-volume objectives to 
input into the TPS optimizer. For the KBP-guided plans, the planner strove to achieve 
the bladder and rectum dose predictions along with originally prescribed physician goals 
 22 
for the target and remaining OARs. Once clinically acceptable target coverage was 
achieved, OAR sparing was optimized until either the KBP dose predictions were 
achieved or target coverage became clinically unacceptable. 
Each set of 31 reference clinical plans and KBP plans were planned on the same 
commercial TPS under the same planning conditions, which included the same planner, 
machine, maximum leaf motion, dose grid resolution, and control point spacing. The 
primary reason for reconstructing the reference clinical plans was to account for the 
variations in these parameters that were used to design the original plans. Keeping 
these parameters and other complexity mitigation tools constant for the reference plans 
and KBP plans was desired in order to make the fairest comparison between these two 
sets of plans. All plans were designed to be delivered on a commercial linear 
accelerator equipped with a 160-leaf MLC (Infinity, Elekta AB, Stockholm, Sweden) and 
were optimized with a maximum leaf motion of 7 mm per degree of gantry rotation 
(mm/deg), dose grid resolution of 4 mm, and control point spacing of 4 degrees. Both 
reference and KBP plans were optimized under the same conditions with the same 
dosimetric endpoints for the target and OARs not including the bladder and rectum. The 
only optimization differences between reference and KBP plans were the bladder and 
rectum planning objectives, where reference plans utilized the original clinical goals and 
KBP plans used the predicted dose-volumes from the KBP method as described 
previously. 
The plan quality of the reference plans and the KBP plans were compared 
qualitatively with DVHs and quantitatively with Wilcoxon signed-rank tests on an array of 
dose metrics at a significance level of p = 0.05. 
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2.2.2. Plan Complexity 
The complexities of reference plans and KBP plans were quantified using the 
total planned MUs, MCS113,120, the edge metric (EM)112, and the average MLC leaf 
motion per degree of gantry rotation (LM). Planned MU values were normalized by the 
fractional prescription dose to enable the comparison between plans of differing 
prescriptions. The MCS was originally introduced by McNiven et al. to assess fixed-
gantry IMRT modulation complexity and was later adapted for VMAT by Masi et al.113,120 
Briefly, the MCS is a metric ranging from zero (most modulated) to one (least 
modulated) that incorporates leaf sequence variability and aperture area variability 
components weighted by their segment contributions. The EM is computed as the 
segment weighted ratio of in-field MLC side length and aperture area, which was 
introduced by Younge et al. to characterize the amount of “edge” in apertures.112 The 
values for the scaling factors used in this work were C1 = 0 and C2 = 1. LM was 
determined by averaging the change in leaf position per degree of gantry rotation 
calculated at each control point in the plan over each MLC leaf within the jaws. 
These metrics were computed directly from the DICOM (Digital Imaging and 
Communications in Medicine) RT Plan files using in-house software.127,128 MCS, EM, 
and LM values of the reference and KBP plans were compared using two-sided paired 
t-tests at a significance level of p = 0.05. Since the distribution of differences between 
reference and KBP plan MUs did not meet the normality assumption of the t-test, a two-
sided paired Wilcoxon signed-rank test was used for comparing MUs. 
2.2.3. Delivery Accuracy 
Each of the 31 reference and KBP plans were delivered on the commercial linear 
accelerator platform for which it was planned (Infinity, Elekta AB, Stockholm, Sweden). 
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Dosimetric measurements were performed using a commercial diode-array housed in a 
water-equivalent phantom (MapCHECK2 and MapPHAN; Sun Nuclear Corporation, 
Melbourne, FL, USA). Each set of plans was delivered on three separate occasions in 
order to reduce effects of measurement noise and fluctuations. The diode array was 
calibrated prior to each measurement session to eliminate the influence of daily 
variations in machine output and detector response. While there are several other 
dosimeters with their own advantages and disadvantages, such as film or EPID panels, 
the MapCHECK2 was used in this study primarily to mimic the clinical protocol used at 
our institution. Additionally, while film and EPID panels provide high spatial resolution 
for relative measurements, they are not ideal absolute dosimeters. Detector arrays also 
measure dose at detector locations more accurately than film due to processing and 
densitometry uncertainties and are easier to use compared to film.114 
Calculated dose distributions were generated for the measurement geometry and 
plane by the TPS and were compared to measured data using gamma analysis in this 
study as described in Chapter 1.1.4. Within gamma analysis, it is important to note the 
role dose normalization plays in the %DD gamma criterion. Two possible normalizations 
are global and local, where the former normalizes dose to the maximum dose in either 
dose distribution and the latter normalizes dose to the dose at the local point being 
evaluated. Typical tolerance limits are set as a percentage of points passing the given 
gamma criteria (i.e. GPR). Task Group No. 218 (TG-218) recently recommended 
tolerance and action limits for GPRs to be greater than or equal to 95% and 90%, 
respectively, using a %DD/DTA gamma criterion of 3%/2mm with global 
normalization.114 
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Percent dose-difference and distance-to-agreement criteria of 3%/3mm, 
2%/2mm, and 1%/1mm with both global and local normalization were used to evaluate 
the agreement between the dose distributions. The 3%/2mm global criterion was 
additionally examined to align with the recent recommendations for universal tolerance 
and action limits from TG-218.114 Gamma passing rates were computed for each plan 
using commercial quality assurance software (SNC Patient, Sun Nuclear Corporation, 
Melbourne, FL, USA), where only points with dose above 10% of the maximum dose 
were included in the analysis. The built-in calculated shift software feature was used to 
account for setup uncertainties. Passing rates of the reference and KBP plans were 
averaged over the three deliveries and statistically compared using two-sided paired t-
tests at a significance level of p = 0.05. 
2.3. RESULTS 
2.3.1. Plan Quality 
Table 2.1 shows how reference plans compare statistically with KBP plans for an 
array of DVH points and dose metrics. While KBP plans showed significant differences 
in some PTV dose metrics compared to reference plans, it should be noted KBP PTV 
doses were clinically acceptable and statistically equivalent to the original clinical PTV 
doses. KBP plans showed significant (p < 0.001) decreases in bladder and rectum 
doses compared to the reference plans. On average, Dmean for the bladder and rectum 
was 6.4 Gy and 8.2 Gy lower for KBP plans compared to reference plans, respectively. 
Average DVHs and the standard errors of the means are shown in Figure 2.1 for the 
reference and KBP plans.  
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Table 2.1. Statistical summary of dose values between reference and KBP plans.Note 
that all doses were normalized so that 95% of the PTV received 76 Gy.
Dose Metric 
Means ± Standard Deviations Wilcoxon p-value 
Reference KBP 
Reference 
vs. 
KBP 
PTV   
D2 (Gy) 78.7 ± 0.9 79.2 ± 1.1 0.001* 
D50 (Gy) 77.4 ± 0.5 77.7 ± 0.8 0.02* 
D98 (Gy) 75.2 ± 0.9 74.8 ± 0.9 < 0.001* 
Dmin (Gy) 67.1 ± 6.6 63.3 ± 7.0 < 0.001* 
Dmean (Gy) 77.3 ± 0.5 77.6 ± 0.7 0.013* 
Dmax (Gy) 79.6 ± 1.3 80.6 ± 1.5 < 0.001* 
V95 (%) 99.7 ± 0.7 99.5 ± 0.8 < 0.001* 
V98 (%) 99.0 ± 1.2 98.4 ± 1.2 0.77 
V100 (%) 94.6 ± 2.3 94.8 ± 1.4 0.98 
V107 (%) 0.02 ± 0.1 0.2 ± 0.5 0.011* 
HI† 0.05 ± 0.02 0.06 ± 0.02 < 0.001* 
CI† 1.4 ± 0.1 1.4 ± 0.06 0.002* 
Bladder    
D10 (Gy) 73.6 ± 6.1 68.4 ± 13.8 < 0.001* 
D30 (Gy) 48.5 ± 18.7 38.2 ± 22.7 < 0.001* 
D50 (Gy) 27.2 ± 18.5 19.5 ± 16.2 < 0.001* 
D65 (Gy) 17.9 ± 15.7 11.6 ± 9.7 < 0.001* 
D80 (Gy) 12.5 ± 13.0 7.7 ± 6.5 < 0.001* 
Dmean (Gy) 35.1 ± 12.8 28.6 ± 12.0 < 0.001* 
Rectum    
D10 (Gy) 72.8 ± 4.6 69.1 ± 7.9 < 0.001* 
D30 (Gy) 51.4 ± 12.1 39.8 ± 17.0 < 0.001* 
D50 (Gy) 35.4 ± 12.8 21.9 ± 12.9 < 0.001* 
D65 (Gy) 24.6 ± 12.9 13.8 ± 9.0 < 0.001* 
D80 (Gy) 15.0± 11.9 8.9 ± 6.5 < 0.001* 
Dmean (Gy) 38.0 ± 8.9 29.8 ± 9.3 < 0.001* 
Left Femoral Head   
D2 (Gy) 40.1 ± 6.7 40.4 ± 7.1 0.019* 
Dmax (Gy) 45.9 ± 10.4 47.8 ± 10.2 < 0.001* 
Dmean (Gy) 26.6 ±5.1 26.1 ± 5.6 0.95 
Right Femoral Head   
D2 (Gy) 39.5 ± 6.8 40.5 ± 7.7 < 0.001* 
Dmax (Gy) 44.8 ± 9.8 47.0 ± 9.3 < 0.001* 
Dmean (Gy) 26.8 ± 5.1 26.6 ± 6.0 0.65 
 
 
 
 
  
(table cont’d) 
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Dose Metric 
Means ± Standard Deviations Wilcoxon p-value 
Reference KBP 
Reference 
vs. 
KBP 
Penile Bulb 
Dmean (Gy) 35.5 ± 18.4 34.9 ± 18.9 0.18 
*Indicates a statistically significant result of p < 0.05 
†Homogeneity and conformity indices were calculated according to their International 
Commission on Radiation Units & Measurements definitions. 
2.3.2. Plan Complexity 
KBP plans were significantly more complex than reference plans in every 
evaluated metric. On average, KBP plans required 143 more MUs (p < 0.001), had 
reduced MCS values of 18% (p < 0.001; indicating increased complexity), had 40% 
higher EM values (p < 0.001), and 47% higher LM (p < 0.001) compared to reference 
plans (Table 2.2). 
Table 2.2. Statistical summary of the differences in complexity metrics between the 
reference and KBP plans. 
Complexity Metric Reference Plans (@ ± !) KBP Re-plans (@ ± !) t-test p-value 
MU 450 ± 83 593 ± 113 < 0.001*† 
MCS 0.5 ± 0.1 0.4 ± 0.1 < 0.001* 
EM 0.06 ± 0.02 0.08 ± 0.01 < 0.001* 
LM (mm/deg) 1.0 ± 0.6 1.5 ± 0.5 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
†Result from two-sided Wilcoxon signed-rank test because the distribution of differences in MUs 
between reference and KBP plans was determined to break the t-test assumption of normality. 
Complexity metrics were shown to be strongly correlated with each other. An 
increase in MUs correlated with more complex MCS, EM, and LM values with Pearson 
correlation coefficients (R) of -0.85 (p < 0.001), 0.91 (p < 0.001), and 0.84 (p < 0.001) 
respectively. Similarly, an increase in complexity in terms of the MCS score correlated 
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strongly with an increase in EM values (R = -0.94; p < 0.001) and LM (R = -0.88; p < 
0.001). Lastly, an increase in EM values corresponded strongly with more LM with R = 
0.85 (p < 0.001). 
 
Figure 2.1. Average DVHs comparing reference clinical plans (solid) and KBP plans 
(dashed) for the 31 patients of each labelled planning structure (a-f). The standard error 
of the means is also included as filled bands with solid (reference) or dashed (KBP) 
edge lines. Note that doses were normalized so that 95% of the PTV received 76 Gy. 
2.3.3. Delivery Accuracy 
KBP plans showed significant reductions in quality assurance outcomes 
compared to reference plans as described by gamma passing rates. For criteria with 
global normalization, KBP plans on average had gamma passing rates that were 1.1, 
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1.6, 3.8, and 7.8 percentage points lower than reference plans at the 3%/3mm (p = 
0.009), 3%/2mm (p = 0.003), 2%/2mm (p = 0.002), and 1%/1mm (p < 0.001) criteria 
respectively. Significant reductions in KBP plan gamma passing rates compared to the 
reference plans were also observed at each evaluated gamma criteria using local 
normalization (Table 2.3). Additionally, it is notable that KBP plans showed significantly 
greater inter-delivery variations (p < 0.05) in gamma passing rates than reference plans 
at each gamma criteria for both global and normalization methods (Table C.1). 
Table 2.3. Statistical summary of the differences in gamma passing rates between the 
reference and KBP plans at different gamma criteria. 
 Gamma 
Criteria 
Reference Plans 
Gamma Pass Rates 
(@ ± !) KBP Plans Gamma Pass Rates (@ ± !) t-test p-value 
G
lo
ba
l 
3%/3mm 98.8 ± 1.3 97.7 ± 2.5 0.009* 
3%/2mm 98.3 ± 1.7 96.6 ± 3.3 0.003* 
2%/2mm 93.8 ± 4.2 90.0 ± 6.8 0.002* 
1%/1mm 69.7 ± 8.7 61.9 ± 11.7 < 0.001* 
Lo
ca
l 3%/3mm 91.8 ± 4.4 88.9 ± 6.6 0.03* 
2%/2mm 87.4 ± 6.0 82.0 ± 9.5 0.003* 
1%/1mm 75.4 ± 8.7 66.5 ± 11.9 < 0.001* 
*Indicates a statistically significant result of p < 0.05 
Patient-specific QA outcomes at the 3%/3mm global gamma criterion for all 
reference plans were greater than 95%. As for the KBP plans, only two plans had 
passing rates of less than 95% but greater than 90%. One KBP plan had a gamma 
passing rate of lower than 90% (87.7%). 
Gamma passing rates were also found to be weakly to moderately correlated 
with the evaluated plan complexity metrics (Table 2.4). For instance, gamma passing 
rates at the 2%/2mm local criterion moderately correlated with MUs (R = -0.47; p < 
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0.001), MCS values (R = 0.42; p < 0.001), EM values (R = -0.40; p = 0.001), and LM (R 
= -0.37; p = 0.003). 
Table 2.4. Pearson correlation coefficients between complexity metrics and gamma 
passing rates. 
  Pearson Correlation Coefficients (p-value) 
 Gamma 
Criteria MU MCS Edge Metric Leaf Motion 
G
lo
ba
l 
3%/3mm -0.37 (0.003*) 0.36 (0.004*) -0.36 (0.004*) -0.33 (0.009*) 
3%/2mm -0.43 (< 0.001*) 0.40 (0.001*) -0.40 (0.001*) -0.38 (0.002*) 
2%/2mm -0.45 (< 0.001*) 0.39 (0.002*) -0.39 (0.002*) -0.36 (0.005*) 
1%/1mm -0.50 (< 0.001*) 0.45 (< 0.001*) -0.46 (< 0.001*) -0.40 (0.001*) 
Lo
ca
l 3%/3mm -0.35 (0.006*) 0.31 (0.02*) -0.29 (0.02*) -0.21 (0.10) 
2%/2mm -0.47 (< 0.001*) 0.42 (< 0.001*) -0.40 (0.001*) -0.37 (0.003*) 
1%/1mm -0.56 (< 0.001*) 0.50 (< 0.001*) -0.50 (< 0.001*) -0.49 (< 0.001*) 
*Indicates a statistically significant result of p < 0.05 
2.4. DISCUSSION 
In this work, VMAT plans for prostate cancer patients designed with an OVH-
guided KBP method were significantly more complex and had significantly lower patient-
specific quality assurance outcomes compared to manually-constructed reference 
plans. While KBP-guided plans led to significant improvements in OAR sparing, the 
values of MU, MCS, EM, and LM were all significantly more complex. In addition, a 
weak to moderate correlation was observed between the analyzed complexity metrics 
and quality assurance outcomes. 
To our knowledge, this work is the first evaluation of plan complexity and 
deliverability of plans derived from an OVH-guided KBP method, whereas other studies 
have reported results from the commercial KBP product, RapidPlan. The observed 
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improvements in KBP plan quality are consistent with previous studies investigating 
KBP methods for prostate cancer.67,76 The OAR dose-volume predictions generated 
from the OVH-guided KBP model are designed to output the lowest achievable dose 
levels based on previous data. The results from this study indicate that the achievability 
of these predictions seem to come at the cost of significant increases in plan 
complexity, which is consistent with the work of Kubo et al.124 On the other hand, 
Tamura et al. reported KBP plans to have similar complexity to reference plans overall. 
They also observed significantly reduced (p < 0.05) leaf travel in KBP plans. Both 
Tamura et al. and Kubo et al. each evaluated 30 prostate patients using the same 
commercial KBP system. It is worth highlighting the differences between the KBP 
method used in the present study and the commercial system (RapidPlan) used in 
these previous studies. Whereas the RapidPlan training algorithm uses model-based 
principal component regression129, the KBP system in this work follows an established 
library lookup algorithm to find the lowest dose achieved among a database of 
previously treated patients with similar in-field OVHs to the new patient.126 Also, as 
mentioned previously in Chapter 2.2.1, standardized Pareto-optimal plans were added 
to the dose database and were found to further improve OAR sparing overall compared 
to using data from manually-constructed clinical plans.125 This distinguishes this OVH-
driven KBP system from RapidPlan’s regression-model technique. Therefore, one 
possible explanation for this discrepancy among previous works could be the 
differences in dose objectives and resulting distributions, i.e., the extent to which one 
study more aggressively pursued a better plan result than the other. Further, the 
differences between previous findings and our results may be explained by the differing 
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KBP techniques and also differences in the quality of the underlying dose databases 
these KBP systems used to generate their dose objectives. While KBP plans in both 
previous studies achieved similar dose to clinical plans overall, KBP plans reported by 
Kubo et al. showed significantly lower mean bladder dose along with significantly higher 
MUs and more complex MCS values. Our study achieved similar bladder dose 
reductions as Kubo et al. These results therefore suggest the possibility that increased 
complexity may be required in order to meet the “ideal” dose objectives, in which case 
efforts to mitigate complexity may reduce the quality of the KBP-guided dose 
distributions. 
We did not observe a strong correlation between improved bladder mean dose 
and increased complexity and only a moderate (R ≥ 0.48) correlation between improved 
rectum mean dose and increased complexity (Figure C.4). Plan complexity metrics were 
also not strongly correlated with gamma passing rates. This observation is consistent 
with previous works113,130 and could indicate the selected plan quality metrics cannot 
fully describe plan complexity, even though available evidence suggests a relationship 
does exist. While there have been studies showing increased monitor units are 
necessary for achieving desired dose distributions for certain IMRT cases with complex 
geometry131, other studies have observed instances of unnecessary VMAT plan 
complexity and were able to reduce complexity without substantially impacting plan 
quality using complexity penalties.112 As Mohan et al. noted, the amount of possible 
complexity reduction is dependent on the difficulty of the underlying treatment 
plan.131,132 However, it remains uncertain whether the increased complexity observed in 
the KBP plans of this study was required for the improved OAR dose. Further 
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investigation into what extent the complexity of these KBP plans could be mitigated by 
exploring different TPS optimization settings is warranted. 
The clinical implications of increased plan complexity and reduced delivery 
accuracy have been studied extensively, which served as a primary motivation for this 
study. Investigators such as Younge et al. have implemented aperture complexity 
penalties into the plan optimization stage to limit plan complexity without degrading plan 
quality.112 Others have examined how an array of metrics that quantify beam complexity 
(such as leaf travel in addition to plan irregularity and modulation) correlate with delivery 
accuracy and pre-treatment verification results.119,121 Valdes et al. recently showed the 
feasibility of using machine learning techniques to accurately predict gamma passing 
rates of IMRT plans using many complexity features.95,96 It is possible that further 
accounting for plan complexity using these similar methods during the optimization 
stage could reduce KBP’s observed impact on complexity on a plan-specific level, 
thereby providing a more accurate delivery. This is an avenue of research we plan on 
investigating in future work. 
This study had several limitations. Planning time was not explicitly recorded in 
this research since KBP has been extensively shown to improve planning 
efficiency.44,46,52,53 However, average KBP planning time was qualitatively comparable 
to average reference planning time in the present study. Also, standard clinical values 
for control point spacing and dose grid resolution were used in this work. While it is 
possible  increasing the resolution of these two parameters could mitigate the observed 
differences in calculated and measured KBP dose113, the settings used in this study 
have been shown to provide an acceptable balance of calculation accuracy and 
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speed.133,134 Also, the leaf motion was not constrained beyond the default limits of the 
modeled linear accelerator. It is possible that adjusting these specific optimization 
parameters may diminish KBP plan complexity and delivery accuracy deficiencies to an 
extent.135-137 Another potential limitation is that only a limited number of metrics where 
chosen to quantify plan complexity, though the chosen metrics are commonly used in 
the literature.113,121 
The use of a diode-array also presents potential limitations. A previous study 
have observed a slight temperature dependence for individual MapCHECK diodes 
ranging from 0.52% to 0.57%/°C.138 The impact of any existing temperature 
dependence would likely be negligible in the present study as the measurements for 
KBP and reference plans were acquired consecutively and in temperature-controlled 
rooms. Also, other studies have shown an angular dependence to be the factor that 
most affects the accuracy of MapCHECK2 measurements – particularly at gantry angles 
of 90 and 270 degrees – which could potentially affect gamma passing rates.139,140 
While this study did not directly investigate the effects on these temperature and 
angular dependencies on delivery accuracy, the gamma passing rates at clinically-
relevant criterion for the plans in this study were consistent with those observed at our 
clinic for prostate cases. Additionally, the commercial diode array used in this work has 
been shown to provide accurate VMAT QA measurements despite this angular 
dependence.140-142 It is also important to note the results seen here with this specific 
combination of technologies (OVH-guided KBP method, RayStation TPS, Elekta 
treatment machine, and MapCHECK2 diode array) may not hold for different KBP 
methods and planning, delivery, and measurement technologies as evidenced by the 
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results from Tamura et al.123 Regardless, the results of this study indicate that caution is 
needed regarding the effects of plan complexity and quality assurance outcomes when 
implementing any KBP system as they become more clinically prevalent. However, 
these results supplement the available literature showing KBP’s potential in providing 
immediate and substantial clinical impact. In-house OVH-guided KBP systems similar to 
the one described in this work could be developed and implemented clinically without 
disrupting the existing inverse optimization workflow. The KBP system would provide 
patient-specific predicted bladder and rectum dose-volume planning objectives prior to 
planning, and the planner could then strive to meet these KBP goals as they would 
normally. The observed increase in complexity and reduction in QA outcomes from this 
study may warrant additional focus on the quality control of KBP plan delivery. The 
qualified medical physicist would be responsible for monitoring the deliverability of 
VMAT plans designed with any KBP system. Provided that any reduction in QA 
outcomes does not result in consistently unacceptable plans, the substantial potential 
improvement in plan quality provided by KBP systems should persuade the clinical 
physicist to investigate the feasibility of implementing a KBP system within his or her 
institution. 
Our study did not investigate the source of the reduced quality assurance 
outcomes of KBP-guided plans. While it would certainly be important and desirable to 
characterize the specific causes of delivery accuracy discrepancies between KBP and 
reference plans we leave this for future research as it lies outside the scope and 
purpose of the current work. However, there are known categories of uncertainties in 
the IMRT planning and delivery process that include: limitations of the beam model (e.g. 
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MLC modeling, modeling output factors for small fields, etc.), mechanical and dosimetric 
uncertainties of the delivery system (e.g. MLC leaf position and speed errors, gantry 
rotation and table motion stability, beam stability, etc.), and measurement and analysis 
uncertainties (e.g. setup errors).114 Given evidence available in the literature, the 
primary source of error in the discrepancies between KBP and reference GPRs is most 
likely inaccuracies in the TPS dose computation. For instance, Masi et al. observed 
increased GPRs with plans optimized with a finer control point spacing compared to 
plans of similar complexity optimized with a courser control point spacing.113 Therefore, 
since the KBP and reference plans were optimized under the same TPS settings, the 
resulting differences in GPRs may primarily be caused by limitations in the TPS’s ability 
to accurately model and compute dose of plans of higher complexity. Increasing the 
control point spacing resolution during KBP plan optimization could mitigate the 
observed delivery errors to some extent, but future work is needed to fully describe the 
specific sources of error. KBP effects on plan complexity and gamma passing rates for 
different treatment sites, such as the head and neck, would also be instructive to 
explore. But overall, this research gives reason to further validate and verify all aspects 
of the treatment workflow when implementing KBP systems, whether they be 
established in-house or commercially available methods. 
2.5. CONCLUSION 
While KBP methods have been shown to improve the quality and consistency of 
treatment plans across institutions, the results of this study suggest their use can 
significantly increase plan complexity and reduce patient-specific QA outcomes. An in-
field OVH-guided KBP method was used to generate 31 VMAT plans for previous 
prostate cancer patients. KBP plans showed significantly reduced bladder and rectum 
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dose but were significantly more complex compared to reference plans. The KBP plans 
showed a significant reduction in delivery accuracy - as measured by patient-specific 
QA measurements. These results demonstrate that care should be taken when 
implementing KBP models to ensure resulting plans achieve acceptable quality and 
deliverability. 
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3. APPLICATION AND COMPARISON OF MACHINE LEARNING 
MODELS FOR PREDICTING QUALITY ASSURANCE OUTCOMES IN 
RADIATION THERAPY TREATMENT PLANNING 
3.1. PURPOSE 
The purpose of this study was to develop, validate, and compare different 
machine learning models for predicting quality assurance outcomes of VMAT treatment 
plans. 
3.2. MATERIALS AND METHODS 
3.2.1. Data 
This study was approved by the Institutional Review Board at Louisiana State 
University under IRB# E11428 (see Appendix A). In total, 500 dataset samples were 
collected and anonymized from patients who were previously treated with VMAT at our 
institution. The specific data collected from each patient case consisted of the following: 
the DICOM RT-Plan file, containing the technical parameters of the clinically approved 
treatment plan; the QA measurement file, containing the measured dose acquired 
during QA; and the predicted QA dose output from the TPS. The inclusion criteria for 
each sampled case required each patient to have been previously treated with at least 
one VMAT arc and the subsequent QA measurement to have been performed with a 
MapCHECK2 diode-array housed in a MapPHAN water-equivalent phantom (Sun 
Nuclear Corporation, Melbourne, FL, USA). The diode-array was calibrated prior to 
each measurement to eliminate the influence of daily variations in machine output and 
 
Contents of this chapter were previously published as Wall PDH, Fontenot JD. Application and 
comparison of machine learning models for predicting quality assurance outcomes in radiation therapy 
treatment planning. Informatics in Medicine Unlocked. 2020;18:100292. Reprinted by permission of 
Elsevier Ltd. (Appendix B.2) 
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detector response. All treatment plans were designed using Pinnacle3 (v9.10, Philips 
Healthcare, Amsterdam, Netherlands) and delivered using one of four matched Elekta 
linear accelerators equipped with Agility MLC heads (Elekta AB, Stockholm, Sweden). 
3.2.1.1. Features 
Treatment plan parameters and characteristics were extracted from the DICOM 
RT-Plan file of each sample using in-house software. These parameters were used to 
formulate an array of features that would later be used to develop machine learning 
regression models for predicting QA outcomes. This consisted of 241 raw features, 
which can be categorized into the 23 groups of treatment plan parameters and 
complexity metrics listed in Table 3.1. 
Table 3.1. Summary of 23 feature groups assembled for this study. 
Feature Group Reference(s) Notes 
Modulation 
Complexity Score 
(MCS) 
McNiven et 
al.120 and Masi 
et al.113 
– 
Edge Metric (EM) Younge et al.112 – 
Leaf Travel (LT) – 
Total leaf travel per leaf; includes 1st, 2nd, 3rd, 
4th, and 5th moments unweighted and 
weighted by segment MU 
   
Leaf Motion (LM) – 
Defined as average leaf travel per degree of 
gantry rotation; includes 1st, 2nd, 3rd, 4th, and 
5th moments unweighted and weighted by 
segment MU 
Arc Length – Total degrees of gantry rotation in plan 
MU Factor – Total planned MUs normalized by fractional dose to specification point 
Number of Arcs –  
Average Jaw 
Position (JP) – 
Feature for each jaw and feature with 
average combined jaw position  
Jaw Travel (JT) – Total travel for each jaw 
Average Jaw 
Motion (JM) – 
Average jaw travel per degree of gantry 
rotation for each jaw; unweighted and 
weighted 
   (table cont’d) 
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Feature Group Reference(s) Notes 
Average 
collimator angle – – 
Aperture Area 
(AA) Du et al.
143 1
st, 2nd, 3rd, 4th, and 5th moments unweighted 
and weighted by segment MU 
Aperture 
Perimeter (AP) Du et al.
143 1
st, 2nd, 3rd, 4th, and 5th moments unweighted 
and weighted by segment MU 
Plan Irregularity 
(PI) Du et al.
143 1
st, 2nd, 3rd, 4th, and 5th moments unweighted 
and weighted by segment MU 
Leaf Gap (LG) – 
Distance between opposing in-field leaf 
pairs; 1st, 2nd, 3rd, 4th, and 5th moments 
unweighted and weighted by segment MU 
Plan Modulation 
(PM) Du et al.
143 – 
Small Aperture 
Score (SAS) Crowe et al.
144 Additional feature included maximum SAS among all control points 
Cross-axis Score 
(CAS) Crowe et al.
144 – 
Fractional Area 
Outside of Circle 
(FAOC) 
Valdes et al.95 1
st, 2nd, 3rd, 4th, and 5th moments unweighted 
and weighted by segment MU 
Nominal Dose 
Rate – – 
Treatment 
Machine – 
One of four dosimetrically matched 
machines 
Treatment Site – – 
Flattening Filter 
Free (FFF) – – 
Three of these feature groups include the following categorical features: (1) the 
specific treatment machine on which the plan was delivered, (2) the treated anatomical 
site, and (3) the use of a specialized high-dose delivery mode. In sum, 29 abdomen, 13 
breast, 36 chest, 13 chest wall, 148 head and neck, 127 lung, 61 prostate, 30 prostatic 
fossa, 32 pelvis, and 11 miscellaneous (knee, spine, and shoulder) treatment plans 
were collected for this study. The remaining 20 feature groups were numerical and 
derived from complexity features found in the literature. For groups characterized by 
distributions, features such as mean, standard deviation, and up to the 5th moment 
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about the mean were extracted. Features were also implemented with and without 
accounting for segment MU weightings where applicable. 
3.2.1.2. Target Values 
GPRs were computed using in-house software from each sample’s predicted QA 
dose file from the TPS and the measured dose from performing the QA. The software 
was modified from existing open-source code for computing the gamma index to 
interface with the input data and to include a feature accounting for setup errors . Setup 
errors were mitigated by shifting the planned dose distribution in 1 mm steps along the 
cardinal axes within a 10 mm radius to search for better agreement. The foundation of 
the computation algorithm and validation procedure was based on previous work.145 
The gamma index for each point was computed with a percent dose-difference criterion 
of 3%, a distance-to-agreement criterion of 3 mm, local normalization, and a 10% dose 
threshold. 
3.2.1.3. Data Processing 
In order to avoid data snooping bias in the development and evaluation of 
machine learning models, the overall dataset was split into a training set and a testing 
set with 400 and 100 samples respectively (i.e. 80%/20% split). Data was split using a 
stratified technique based on the distribution of GPRs to guarantee the testing set be 
representative of the overall population of GPRs. Figure 3.1 shows the differences in 
random and stratified sampling for splitting the data, where the standard randomized 
technique resulted in a test set distribution that was less representative of the total 
distribution compared to the stratified technique. This is particularly pronounced when 
comparing the standard deviation of the two testing set distributions against that of the 
overall distribution in the Figure 3.1 example. The overall GPR distribution of the 
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dataset had a standard deviation of 6.01%, compared to 6.13% and 5.49% for the 
testing sets resulting from a stratified and random sampling, respectively. Therefore, the 
stratified sampling avoids possible sampling bias in the target variable by generating 
training and testing sets with target distributions representative of the overall dataset 
distribution. 
 
Figure 3.1. Histograms of GPR distributions for the entire dataset (blue), training set 
(orange), and testing set (green) when utilizing a random (left) and stratified (right) 
sampling technique. The stratified technique provides training and testing sets with GPR 
distributions sampled proportionally from the entire dataset, which avoids bias from 
over- or under-sampling certain ranges of GPRs as seen with the purely randomized 
technique. 
After splitting the data, categorical features were one-hot encoded to represent 
every category in each feature group as a binary attribute. Feature standardization was 
applied to numerical features, where the mean value was subtracted and the variance 
normalized to one. This transformation was fit to the training data and was then applied 
to the testing set i.e. the testing set data was not used in the initial standardization 
process. 
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3.2.2. Feature Analysis and Selection 
Feature selection is a process used in developing machine learning models that 
can have several benefits. Selecting a subset of the most important features can 
simplify interpretation and visualization of the data, reduce training and utilization times, 
or improve the overall performance and robustness of the predictive model.146 In this 
study, each feature’s relative importance in contributing to the accurate prediction of 
GPRs was quantified and ranked using three different methods: forests of extremely 
randomized decision trees (Extra-Trees), mutual information, and linear regression. 
Decision Trees are a powerful machine learning algorithm that work to search for 
the feature and the decision threshold within that feature that best splits the training 
data into similar response categories. More specifically, the feature and decision cut-
point for each node of a Decision Tree is determined such that the cost function – e.g. 
mean squared error (MSE) between the predicted output and the true value – is 
minimized. Decision Trees are formed deterministically and typically employ a greedy 
training algorithm, where the optimum split is searched for at each decision node. While 
classical Decision Trees are versatile machine learning algorithms and capable of fitting 
complex datasets, they can suffer from overfitting the training data. 
Random Forests are another class of tree-based algorithms developed in an 
effort to reduce model variance found with regular decision trees.147 A Random Forest is 
an ensemble of Decision Trees that grows its trees by searching for the best feature 
among a random subset of features. Random Forests are a bagging technique, where a 
collection of estimators is trained on different random subsets of the training set with 
replacement. Once all of the estimators are trained, the Random Forest ensemble 
aggregates all estimator predictions by averaging them. Generally, the random 
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sampling of the training set results in greater tree diversity, which trades higher bias for 
lower variance for an improved overall model. 
The Extra-Trees algorithm furthers the randomization of Random Forests by also 
using random thresholds for each feature when growing each random Decision Tree, 
rather than searching for the best possible thresholds as in regular Decision Trees and 
Random Forests. This explicit randomization of the cut-points and features combined 
with ensemble averaging have been shown to reduce variance compared to other 
weaker randomization schemes found in other algorithms like Random Forests.148 A 
useful property of Extra-Trees is that the relative importance of each feature can be 
measured incidentally. Relative feature importance is computed by averaging the 
amount each feature contributes to reducing the prediction error over all trees in the 
forest. 
Relative feature importance was calculated in this study by averaging the results 
from 50 different Extra-Trees, where each Extra-Tree forest consisted of 500 trees. 
Standard values were used for other parameters within the Extra-Trees regression 
estimator provided by scikit-learn, which is the open-source machine learning software 
package utilized for feature selection and model development in this study unless 
otherwise specified.149 
Univariate statistical methods using mutual information and linear regression 
were used to quantify relative feature importance to compare with the Extra-Trees 
method. Mutual information is a statistic for measuring the dependency between 
variables. In contrast to linear regression, which only quantify linear relationships 
between data sets, mutual information can detect either linear or nonlinear 
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relationships. Specifically, mutual information is defined as the reduction in uncertainty, 
or entropy, of one random variable due to the knowledge of another random variable.150 
Given two continuous variables A and B with a joint probability density function +(C, D) 
and marginal probability density functions +(C) and +(D), the mutual information E(A; B) 
is the relative entropy between the joint distribution and the product distribution +(C)+(D), or 
 E(A; B) = G +(C, D) log K +(C, D)+(C)+(D)L -C-D'∈)	+∈,   
Mutual information values were computed for each feature to measure their 
dependence relative to the target values. 
Linear regression was used to quantify the linear relationship between the 
feature and target variable space. First, the correlation between each feature set A and 
the target set B was computed as 
 
(A − @))(B − @,)!)!,   
where @ and ! represent the mean and standard deviation respectively. The strengths 
of the linear correlation between each feature and the set of target values were 
computed and used to measure the relative feature importance in this study. 
After relative feature importance was assessed with these three different 
selection methods, different numbers of features were selected for each set of relative 
importance rankings. Specifically, subsets of the 5, 10, 25, 50, 100, 175, and 241 (i.e. 
all features) most important features according to each of the three feature importance 
methods were selected for training a given machine learning model, resulting in 21 
models (three feature selection methods times seven dataset subsets of varying size) 
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for each class of machine learning algorithm. The impact of the number of selected 
features and type of feature selection method on model performance was then 
assessed. 
3.2.3. Training Machine Learning Regression Algorithms 
This study surveyed and evaluated the performance of four different categories 
of machine learning algorithms for this regression problem. Below are brief descriptions 
of each specific algorithm along with the model-specific, tuned hyperparameters 
determined via cross-validated searches. The interested reader can find more details in 
the supplementary material regarding the hyperparameter tuning methods used for 
each model. The tuned hyperparameters of the models discussed in ensuing results are 
also summarized in the supplementary material for convenience (Table C.2). For each 
of the 21 combinations of number of features selected and feature selection methods 
detailed in Chapter 3.2.2, the best predictor was selected from these cross-validated 
searches and were then refit to the entire training set. This optimized fit was evaluated 
on the testing set and was used to compare the performance of different learning 
algorithms and to assess the impact of number of features selected and type of feature 
selection method on model performance. 
3.2.3.1. Linear Regression Models 
One of the simplest machine learning models is linear regression. A linear model 
makes a prediction by computing a weighted sum of the input features, plus a constant 
bias term. This equation for linear regression model prediction can be expressed as 
 DN = ℎ-(P) = Q# ∙ P  
where DN is the predicted value, θ is the model’s parameter vector containing the bias 
term θ. and the feature weights θ/ to Q0, P is the instance’s feature vector (containing C. 
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to C0, with C. always equal to 1), and ℎ- is the hypothesis (i.e. prediction) function, using 
the model parameters Q. Training a linear regression model means finding the set of 
parameters such that the model best fits the training set. This can be done by finding 
the parameter vector Q that minimizes the MSE, defined as 
 MSE(X,  ℎ-) = Z1\]^_ℎ-_P(2)` − a(2)`4567/   
where \ is the number of instances in the dataset, P(2) is a vector of all the feature 
values of the ith instance in the dataset with a(2) being its associated target value (the 
desired output value for that instance), X is a matrix containing all the feature values of 
all instances in the dataset, and ℎ- is the system’s prediction or hypothesis function 
parametrized by Q. 
A strategy to reduce the likelihood of overfitting in linear regression and other 
machine learning models is to regularize, or constrain, the weights. In addition to 
unregularized linear regression, three types of regularized linear models were explored 
in this study: Ridge Regression, Lasso Regression, and Elastic Net. Ridge Regression 
adds an ℓ&-norm regularization term to the cost function, equal to 8& ∑ Q6&067/ , where d is a 
hyperparameter to control the amount of regularization.151 Similarly, Lasso Regression 
instead adds an ℓ/-norm regularization term to the cost function, equal to d ∑ |Q6|067/ .152 
Both algorithms include the hyperparameter d to control the amount of regularization. 
Elastic Net utilizes both regularization terms found in Ridge Regression and Lasso 
regression and allows control of each type of regularization through a mixing parameter &; Elastic Net is equivalent to Ridge Regression when & = 0 and equivalent to Lasso 
Regression when & = 1. Therefore, since the hyperparameter optimization of the Elastic 
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Net model included both Lasso and Ridge Regression models, only Elastic Net results 
are shown here for simplicity. The Elastic Net hyperparameters d and & were tuned to 
0.594 and 1, respectively, via a 10-fold cross-validated grid search. 
3.2.3.2. Support Vector Machine 
SVMs are powerful and versatile models capable of performing linear or 
nonlinear classification and regression. SVMs implement kernels to map input features 
to higher dimensional spaces to facilitate nonlinear predictive modeling. The SVM 
regression algorithm originally proposed by Drucker et al. depends on only a subset of 
the training set such that if the predicted value is within a certain tolerance f, the loss is 
zero, while if the predicted point is outside this f-tube, the loss is the magnitude of the 
difference between the predicted value and the radius f of the tube.153 Therefore, SVMs 
are f-insensitive, where adding training instances within the f margin does not affect 
model predictions. 
The linear, polynomial, Gaussian Radial Basis Function (RBF), and sigmoid 
kernels were tested in this study. Each are defined as 
 Linear:  g(h, i) = h# ∙ i  
 Polynomial:  g(h, i) = (;h9 ∙ i + &):  
 Gaussian RBF:  g(h, i) = exp	(−;‖h − i‖&)  
 Sigmoid:  g(h, i) = tanh(;h9 ∙ i + &)  
where ; and & are kernel hyperparameters. Tuned hyperparameters for SVMs were 
optimized via a 5-fold cross-validated randomized search with 250 iterations (Table 3.2). 
Table 3.2. Selected hyperparameter values for the SVM model. 
SVM Parameter Selected Value 
Kernel Gaussian RBF 
C 6.407 f 0.094 
  (table cont’d) 
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SVM Parameter Selected Value ;  
(for Polynomial,  
Gaussian RBF,  
and Sigmoid kernels) 
1q;$<=>%$? × !& 
Note: !! is the variance of the given feature distribution 
3.2.3.3. Tree-Based Regression 
3.2.3.3.1 Decision Trees 
As mentioned previously in Chapter 3.2.2, Decision Trees are flexible algorithms 
capable of classification or regression tasks and can even predict multiple outputs. 
While they can fit complex datasets, Decision Trees are nonparametric models that 
have a strong tendency to overfit the training data if left unconstrained or not regularized 
appropriately. Regularization parameters for the tuned Decision Tree model in this study 
were determined to be a maximum tree depth of 3, a minimum number of samples 
required at each node of 17, with the mean absolute error (MAE) loss function used to 
measure the quality of a split. Standard values were used for remaining model 
parameters during training. The Classification and Regression Tree (CART) algorithm 
introduced by Breiman et al. was used to train the decision tree models in this work.154 
3.2.3.3.2 Random Forests 
Random Forests are a class of machine learning algorithm consisting of an 
ensemble of Decision Trees which are grown by searching for the best feature among a 
random subset of the feature space, instead of searching for the best among all 
features as in normal Decision Trees. As indicated in Chapter 3.2.2, this increases bias 
and decreases variance to generally yield a better model overall. The same tree-
growing hyperparameters and their associated ranges of values given in Chapter 
3.2.3.3.1 were similarly optimized for Random Forests. The optimized Random Forest 
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model had a maximum tree depth of 12, a minimum number of samples required at 
each node of 4, and an MSE loss function. Additionally, the number of trees in the 
optimized forest was determined to be 124. 
3.2.3.3.3 AdaBoost 
Boosting algorithms are those incorporating and combining an ensemble of weak 
models into a stronger composite model. This process is generally sequential, where 
subsequent models are trained based on the errors of the preceding model. AdaBoost 
is a popular boosting learning algorithm that begins by fitting a base regressor to the 
training data and then iteratively fits copies of the regressor on the same dataset while 
adjusting the relative weights of training instances associated with the largest errors.155 
A standard Decision Tree with a maximum depth of 5 levels was the base 
regression model used for optimizing and training the AdaBoost models in this study. 
The optimized AdaBoost-specific hyperparameters of describing the maximum number 
of estimators at which boosting was terminated and learning rate, which scales the 
contribution of each regressor, were determined to be 91 and 1.311 respectively. 
3.2.3.3.4 Gradient Boosting 
Gradient Boosting is another popular boosting algorithm that differs from 
AdaBoost, which adjust instance weights at every iteration, by fitting new predictors to 
the residual errors made by the previous predictor.156 This allows for optimization of 
arbitrary differentiable loss functions, where each predictor is fit on the negative gradient 
of the given loss function at each iteration. 
Like with the AdaBoost models, Decision Trees were used as the base 
regression model for training and optimizing Gradient Boosting models. The determined 
hyperparameter values for the optimized Gradient Boosting model were a maximum 
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number of estimators of 616, a learning rate of 0.007, a fraction of training samples to 
be used for fitting the individual base predictors of 0.444, a maximum tree depth of 14, 
and a minimum number of samples required to split an internal node of 6. 
3.2.3.4. Artificial Neural Network 
Artificial Neural Networks (ANNs) are popular machine learning algorithms that 
take inspiration from the biological architecture found in the brain. ANNs are commonly 
used models due to their robustness and scalability, which makes them useful for large 
and complex tasks like mastering the game of Go.157 
Hyperparameter tuning in neural networks is a challenging problem given the 
potentially large parameter space. Although the number of tunable parameters gives 
ANNs their flexibility, the topology of even a simple network can be altered by 
parameters such as the number of hidden layers, the number of neurons per layer, the 
type of activation function used in each layer, among others. 
Neural networks in this study were developed using Keras.158 The set of 
hyperparameters yielding the best validation MAE (20% of training set) was chosen as 
optimal and were used for final training and testing. Table 3.3 lists the optimized 
hyperparameter values for the ANN model. 
Table 3.3. Selected hyperparameters for the ANN model. 
Talos-specific hyperparameter Tuned Parameters 
Learning Rate 0.280 
Number of neurons in first layer 27 
Batch Size 94 
Number of hidden layers 3 
Topology Shape† ‘funnel’ 
Epochs 275 
Dropout 0 
  
(table cont’d) 
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Talos-specific hyperparameter Tuned Parameters 
Optimizer Nadam 
Losses MAE 
Hidden layers activation function Linear 
Output layer activation function relu 
†Topology shapes are package-specific names where ‘brick’ assigns the same number of 
neurons in each layer, ‘triangle’ decreases the number of neurons by a constant number with 
each layer so that the shape resembles a triangle, and ‘funnel’ decreases the number of 
neurons by floor of the difference between the specified number of neurons in the first layer 
and last layer divided by the number of desired hidden layers, resulting in a funnel shape. 
3.2.4. Overall Model Comparison 
Once optimal hyperparameters were selected via cross-validated searches as 
described in Chapter 3.2.3, models for each type of algorithm, feature selection method, 
and number of selected features were evaluated on the separate testing set that was 
unseen during training. Models with the best MAE within each class of learning 
algorithm were used to compare overall performance. It is important to note MAE is 
reported as a percentage in this work because the variable being evaluated (GPR) is 
expressed as a percentage. Specifically, MAE is defined in this study as: 
 stu = ∑ |DN6 − D6|067/ q   
where DN6 is the predicted GPR and D6 is the true GPR. Since GPRs are the percentages 
of points passing the given gamma criteria, the individual absolute errors |DN6 − D6| and 
therefore the MAE of predicted GPRs are expressed as percentages. Further, values of 
MAE in this work should not be confused with mean absolute percentage errors. 
Top performing models were selected to further assess the impact of suspected 
outliers among the labeled data (i.e. GPRs), which was performed by iteratively 
removing samples with GPRs outside 1.5 times the interquartile range (25%-75% 
distribution quartiles). Performance for these top performing models was also 
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statistically compared using Wilcoxon signed-rank tests (with significance level set at p 
= 0.05) to “random guessing” by fitting the training and testing datasets to Gaussian 
distributions and then randomly sampling those distributions to obtain ‘random’ 
predictions. 
3.3. RESULTS 
3.3.1. Feature Analysis 
Relative feature importance was measured using three feature selection 
methods: forests of Extra-Trees, mutual information, and linear regression. Table 3.4 
shows the relative importance of each feature category – according to the sum of 
feature importances of each individual feature within each category – for each of these 
three selection methods. The SAS feature category was most important for each 
selection method. Generally, feature groups related to aperture size and shape or MLC 
leaf gaps (e.g. FAOC, LG, etc.) were also important for accurately predicting GPRs. 
Regarding the raw features within each feature category, the five most important 
features using forests of Extra-Trees were (in order of decreasing importance) the lung 
treatment site, the prostatic fossa treatment site, the mean weighted LG, the mean 
collimator angle, and maximum SAS at 40 mm. The five most important features with 
the mutual information feature selection method were the mean weighted FAOC at 25 
mm, the SAS at 75 mm, the mean weighted LG, the SAS at 80 mm, and the SAS at 45 
mm. Lastly, the five most important features using the linear regression method were 
the SAS at 50 mm, the SAS at 45 mm, the SAS at 55 mm, the maximum SAS at 45 
mm, and the SAS at 60 mm. It is interesting to note the differences in feature 
importance among the three selection methods. The two most important features using 
forests of Extra-Trees were lung and prostatic fossa, both of which are treatment sites. 
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Whereas for the mutual information and univariate linear regression methods, the top 
features were related to aperture shape and the size of the gaps between opposing 
MLC leaves. Features were weakly correlated with GPRs, with SAS 50 mm having the 
Pearson correlation coefficient with the largest magnitude of 0.38 (p < 0.001; Figure 
3.2). Overall, 113 out of the 241 raw features having significant p-values of less than 
0.05 and 32 features had correlation coefficient magnitudes of at least 0.3. 
Table 3.4. Rankings of relative importance of feature categories according to the sum of 
all raw features within each classification for each feature analysis method. 
Summed 
Feature 
Rank 
Extra-Trees Mutual Information Linear Regression 
1 SAS SAS SAS 
2 FAOC FAOC LG 
3 Site PI FAOC 
4 LT LG AA 
5 AP LM Site 
6 LM LT JT 
7 PI AA EM 
8 LG AP FFF 
9 JM Site Dose Rate 
10 Machine JP MU Factor 
11 AA JM AP 
12 JT JT JM 
13 Collimator Angle MU Factor PI 
14 JP EM LM 
15 Arc Length Machine Machine 
16 MU Factor CAS LT 
17 FFF FFF JP 
18 Dose Rate Dose Rate Collimator Angle 
19 CAS Collimator Angle Arc Length 
20 MCS MCS Number of Arcs 
21 EM PM MCS 
22 PM Arc Length CAS 
23 Number of Arcs Number of Arcs PM 
Figure 3.3 shows the distribution of dataset GPRs as a function of treatment site. 
Lung had the highest mean GPR overall of 91.05% with a standard deviation of 6.67%, 
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while prostatic fossa had the lowest mean GPR of 83.35% with a standard deviation of 
6.29%. Additionally, lung had the most samples with GPRs less than or equal to 80% (n 
= 10) while prostatic fossa had the highest proportion of samples that had GPRs less 
than or equal to 80% (30%). 
 
Figure 3.2. Scatter plot of GPR vs. SAS – 50 mm over the dataset along with the 
Pearson correlation coefficient (R). Note the feature axis has been standardized. 
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Figure 3.3. Distribution breakdown of dataset with respect to treatment site. Here, the 
grey circles indicate the distribution mean and crosshairs indicate values lying outside 
1.5 times the interquartile (25%-75%) range. 
3.3.2. Optimized Model Performance 
After relative feature importance was quantified using the three selection 
methods, different machine learning algorithms were trained using subsets of varying 
numbered selected features as determined by each method. Hyperparameters were 
optimized for each learning algorithm and feature set pair using a cross-validation 
searching method as described in Chapter 3.2.3. Each model was trained and 
subsequently evaluated on the testing set, after which the models within each class of 
algorithm with the lowest test MAE was selected for comparison (Table 3.5). Optimized 
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hyperparameters for each model listed in Table 3.5 can be found in the supplemental 
material. 
Table 3.5. Testing error for best performing model within each class of learning 
algorithm with associated feature selection method and number of features. Mean and 
standard deviations of testing error from cross-validation is also included. Note that all 
models underwent 10-fold cross-validation, except for SVM, for which 5 folds were 
used. 
Algorithm Cross-Validation MAE (@ ± !;	%) Test MAE (%) Feature Selection Method Number Of Features 
Linear Regression 4.20 ± 0.57 4.29 ET 5 
Elastic Net 4.34 ± 0.69 4.17 LR 50 
SVM 3.96 ± 0.42 3.85 LR 100 
Decision Tree 4.37 ± 0.72 4.14 LR 10 
Random Forest 3.91 ± 0.60 3.98 ET 100 
AdaBoost 3.99 ± 0.51 3.98 ET 50 
Gradient Boosting 4.06 ± 0.52 3.94 ET 50 
ANN 4.24 ± 0.69 4.01 ET 50 
Abbreviations: LR = Linear Regression; ET = Extra-Trees 
Mean cross-validation MAE was consistent with test MAE for each learning 
algorithm, indicating the models generalized as expected from training to testing. The 
best (i.e. lowest) MAE on the testing set was the SVM model (3.85%) followed by the 
Gradient Boosting model (3.94%). Random Forest and AdaBoost models also achieved 
test MAEs of less than 4%. In addition, the optimal number of features for each model 
seemed to be between 50 and 100 of the most important features according to ranking 
with Extra-Trees and linear regression feature selection methods. 
3.3.3. Top-Performing Models 
The top two performing models, SVM and Gradient Boosting, were selected for 
further inspection and analysis. Figure 3.4 shows the behavior of cross-validation error 
as a function of feature selection method and number of features selected for each 
model. Generally, the cross-validation error decreased as the number of selected 
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features increased for both models but plateaued after 100 selected features. SVM 
models using the Extra-Trees and linear regression feature selection methods resulted 
in lower cross-validation error than the mutual information method when using higher 
numbers of features. Also, cross-validation error for both models using the Extra-Trees 
feature selection varied less with the number of selected features compared to mutual 
information and linear regression selection methods. 
 
 
Figure 3.4. Cross-validation MAE of SVM (a) and Gradient Boosting (b) models as a 
function of feature selection method and number of selected features. The mean cross-
validation error and standard deviation is plotted. Note that 5 folds were used for SVM 
models and 10 folds were used for Gradient Boosting models. 
The impact of the number of training samples on training and cross-validation 
error was also assessed for these models. Figure 3.5 shows these learning curves 
(which plot training and cross-validation error against number of training samples) for 
the optimized models. The SVM learning curve shows the validation error gradually 
decreasing with increasing training samples, while the training error stabilizes after 
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about 75 training samples. The Gradient Boosting learning curve shows training and 
validation error to also be decreasing with the size of the training set. However, the 
difference in the training and validation errors for the Gradient Boosting model highlight 
the tendency of Decision Trees to overfit the training data compared to the SVM model. 
 
 
Figure 3.5. Learning curves, which plot error as a function of the number of training 
samples, for the optimized SVM (a) and Gradient Boosting (b) models. Note that 10-fold 
cross-validation was used for both models to construct these curves. Average values 
resulting from cross-validation are shown via markers, with the associated standard 
deviation given via the shaded regions. 
Composite testing error results from 5-fold cross-validation over the entire 
dataset for the SVM and Gradient Boosting models are shown in Figure 3.6 and Figure 
3.7 respectively. The SVM model resulted in 3.75 ± 0.29% (mean ± standard deviation) 
testing MAE while the Gradient Boosting model resulted in 3.81 ± 0.22% MAE. This 
represents a significant 41.1% (p < 0.001) and 40.6% (p = 0.02) average improvement 
respectively over “random guessing,” which had an MAE of 6.41 ± 4.98%. The SVM 
model predicted 51.2% and 74.4% of the testing samples to within 3% and 5% error, 
respectively. Whereas the Gradient Boosting model predicted 47.2% and 71.2% of the  
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Figure 3.6. 5-fold cross-validation testing performance for the optimized SVM model. (a) 
and (c) plot the true GPR values against the predicted GPR values from the model 
when trained and tested with the full dataset and when trained and tested with 
suspected outliers removed from the dataset, respectively. (b) and (d) are associated 
histograms of the differences between the true and predicted values. 
testing samples to within 3% and 5% error, respectively. The maximum errors were 
23.7% and 17.8% for the SVM and Gradient Boosting models respectively. When 
suspected outliers were removed from the dataset, the average testing MAE improved 
by 0.41% and 0.47% for the SVM and Gradient Boosting models respectively. Most 
noticeably, the percentages of instances with errors less than 10% were improved from 
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94.2% to 96.64% and from 95.8% to 98.32% for the SVM and Gradient Boosting model 
respectively when removing these suspected outliers. 
 
 
 
Figure 3.7. 5-fold cross-validation testing performance for the optimized Gradient 
Boosting model. (a) and (c) plot the true GPR values against the predicted GPR values 
from the model when trained and tested with the full dataset and when trained and 
tested with suspected outliers removed from the dataset, respectively. (b) and (d) are 
associated histograms of the differences between the true and predicted values. 
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3.4. DISCUSSION 
This study collected a large retrospective dataset of VMAT plan and QA data in 
order to investigate the feasibility of developing machine learning models for predicting 
GPRs from an array of treatment plan parameters and complexity metrics. The selected 
features were found to be weakly correlated with the target variable, which resulted in 
the best-performing machine learning model (SVM) yielding an average cross-validated 
test MAE of 3.75%. These results may reveal potential limitations within the present 
dataset when compared to model performance in existing literature such as in Valdes et 
al., which reported being able to predict GPRs for fixed-gantry IMRT plans to within 
3%.95 However, each machine learning model investigated in this study achieved 
improved testing MAE compared to “random guessing” and was able to capture the 
overall relationship between the independent and dependent variables present in the 
available dataset. 
Several previous studies have showed promising results for predicting GPRs for 
“fixed-gantry” IMRT plans using machine learning and deep learning.95-99 Fewer studies 
have been published concerning VMAT QA. Granville et al. recently applied an SVM 
model for classifying results of VMAT QA measurements performed with biplanar diode 
arrays into ‘hot’, ‘cold’, or ‘normal’ median dose difference categories.122 Ono et al. used 
regression tree analysis, multiple regression analysis, and ANNs to predict GPR 
measurements using a helical diode array based on plan complexity metrics.101 Novel 
aspects of this study compared to these previous works are the comprehensive 
comparison of different standard machine learning models, the investigation of feature 
importance using three different selection methods, and the assessment of the 
relationship between both the number of features and the type of selection method used 
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during training and the resulting model performance. The SVM model was found to be 
the best-performing model and the machine learning algorithms generally performed 
better with fewer number of features selected with either forests of Extra-Trees or linear 
regression. Additional strengths of this study are the collection of a large dataset along 
with inspecting a large array of plan complexity metrics and features. Although the 
features were found to be weakly correlated with the target variable overall, more than 
100 features were significantly (p < 0.05) correlated. The feature selection methods 
used were able to improve model performance compared to models trained with all 
available features as shown in Table 3.5, which indicates reducing the number of 
selected features provided the best performance across all models, in addition to 
reducing model dimensionality. Also, the specific combination of technologies (Pinnacle 
TPS, Elekta LINACs, and MapCHECK2 diode-array) used in this study is unique relative 
to previous studies using machine learning to predict GPR measurements to our 
knowledge. 
An interesting result from analyzing the relative feature importance in accurately 
predicting GPRs was that the lung and prostatic fossa treatment sites were the two 
most important features according to the forests of Extra-Trees selection method. Unlike 
previous studies, which have not included treatment site as an input feature, this result 
could indicate the need for site-specific models. This is similar to the results Valdes et 
al. observed, where one treatment machine was found to have different profile 
characteristics affecting model performance that suggested machine-specific models 
may lead to more robust predictions. Further research and a larger number of samples 
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within each treatment site are warranted in the future to evaluate differences in site-
specific models. 
The present work shares similarities with previous studies such as the number of 
samples and the plan complexity metrics and parameters included in the feature space. 
The features selected for this study (which were taken or adapted from the literature 
listed in Table 3.1) showed weaker correlations with the target GPR values than the 
correlations found in previous studies for those same features.112,113,120 However, 
features based on the aperture size (e.g. SAS) were found to have the strongest linear 
correlation with GPRs (Figure 3.2), which is consistent with Crowe et al.144 The weaker 
correlations found in this study could be a result of differences in the underlying data in 
each work, such as the institution-specific combination of technologies and clinical 
protocols utilized for treatment planning QA. 
The differences in testing errors between this study and previous results may be 
due to the spread in the distribution of GPRs in the present dataset. The majority of 
GPR distributions in these previously mentioned studies were heavily concentrated 
towards the 100% GPR boundary, which potentially clouds the true relationship 
between features and dose differences. In contrast, the target distribution used in this 
study had an average value of 89.39% and a standard deviation of 6.01%. The percent 
dose-difference/distance-to-agreement gamma index criteria of 3% and 3 mm with local 
normalization was selected for this study to enable comparison with previous studies 
and to obtain a target distribution with meaningful information about the underlying 
differences between planned and measured dose distributions. It is also important to 
note each sample used in the study passed the clinical QA protocol at our institution. 
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The GPRs reported here were computed without incorporating measurement 
uncertainty (which is typically turned on for clinical evaluation) associated with the 
device due to factors such as, temperature change, accelerator output fluctuation, array 
calibration accuracy, and electronic measurement precision. 
Training time was not considered for the purposes of this study but is still 
important to contemplate prior to clinical implementation. Training times qualitatively 
varied depending on the type of machine learning algorithm, number of features used, 
and the number of iterations executed for hyperparameter optimization searches. 
However, for each of the machine learning models in this study, once the model has 
been trained and has had its hyperparameters tuned, real-time predictions can be 
given. Therefore, predictions can be quickly provided during a clinical scenario given the 
necessary input features for the model. 
It is possible the correlation between plan complexity and GRPs in this study was 
also limited by the 1 cm minimum leaf gap constraint used at our institution. Additionally, 
all but four samples in the dataset utilized four degrees for control point spacing during 
VMAT plan optimization. Using a finer gantry spacing resolution could result in more 
accurate dose computation, although four degrees has been shown to provide an 
optimal balance between plan quality and complexity.113,135 Further, the specific 
combination of technologies and clinical techniques – such as the radiation-delivery 
machine, the TPS software and optimization settings used to design the clinical 
radiation treatment plans, the measurement device and analysis technique used for 
performing QA, etc. – used in this study could also have led to a dataset with weaker 
relationships between plan features and delivery errors. For example, the 1 cm 
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minimum leaf gap constraint likely restricted the possible range of complexity for the 
plans in this study’s dataset, which could have led to weaker correlations with QA 
outcomes when compared to studies with plans with a looser leaf gap constraint. 
Differences in these types of underlying factors that characterize the feature-target 
relationship possibly prevented the machine learning algorithms surveyed in this work to 
achieve error rates as low as previously reported in IMRT and VMAT QA studies. 
However, each machine learning model was able to achieve a minimum of 37% 
improvement over “random guessing,” with the top-performing SVM model improving by 
41.1%. Therefore, it is important to note that results from the present and previous 
studies are specific to the particular dataset used, which warrants future research 
investigating how the relationship between complexity features and QA outcomes 
behaves as a function of varying delivery, planning, and QA parameters. 
Previous investigators have noted the numerous clinical benefits of models for 
predicting VMAT QA measurements. Most notably, a machine learning model could 
identify a treatment plan that is predicted to present unacceptable dose delivery errors 
before measurement, allowing the plan to be modified beforehand to save time. 
Alternatively, a machine learning model for predicting GPRs for VMAT plans could be 
inserted into the planning stage to provide QA-based information to the optimizer and 
planner in real-time. Predicted GPR output from a machine learning model could be 
added to the optimization cost function to penalize search solutions that reduce the 
predicted GPR, which would result in a plan guided by both plan quality (e.g. dose-
based) and delivery accuracy (e.g. QA-based) endpoints. Our group is currently 
pursuing this avenue of research. Previous works have also investigated the feasibility 
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of developing convolutional neural networks to predict GPRs based on fluence maps for 
fixed-gantry IMRT and were able to achieve comparable performance to machine 
learning models based on complexity metrics.97 While the purpose of this work was 
specifically to perform a systematic evaluation of different machine learning models for 
predicting VMAT QA outcomes based on complexity features, a logical next progression 
would be to develop a convolutional neural network for predicting VMAT QA outcomes 
to mirror the progression of previous literature on predictive models for fixed-gantry 
IMRT QA. 
3.5. CONCLUSION 
Models predicting VMAT QA outcomes can help improve clinical efficiency by 
highlighting treatment plans likely to fail QA prior to measurement. This work is among 
the first to investigate and compare several machine learning algorithms for predicting 
VMAT QA measurements using the specific planning and measurement technologies at 
our institution. Model features were based on treatment plan complexity metrics and 
parameters and their relative importance in accurately predicting GPRs was assessed 
via forests of Extra-Trees, mutual information, and linear regression. Features were 
found to be weakly correlated with GPRs, resulting in a test MAE of 3.75% for the best 
performing model (SVM). While previous studies have shown the ability of machine 
learning models to predict QA outcomes with a high degree of accuracy, the results of 
this study show model performance may be limited by characteristics of the underlying 
data, particularly the unique and specific combination of technologies and clinical 
parameters used to generate treatment plans and perform quality assurance. Further, 
machine learning models were developed and shown to be significantly better than 
“random guessing,” but the results from this study indicate feature analysis and 
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selection should be performed when establishing a machine learning model for 
predicting QA measurements.
69 
4. USE OF MACHINE LEARNING ALGORITHM DURING 
OPTIMIZATION TO IMPROVE PATIENT-SPECIFIC QUALITY 
ASSURANCE IN VOLUMETRIC MODULATED ARC THERAPY 
PLANS 
4.1. PURPOSE 
The purpose of this study was to evaluate the feasibility of a QA-based planning 
tool, whereby QA outcomes for VMAT treatment plans are directly optimized using 
machine learning without substantially degrading the dosimetric quality of the original 
plan. 
4.2. MATERIALS AND METHODS 
4.2.1. Description of Algorithm 
An in-house algorithm was developed to optimize predicted QA endpoints by 
modifying existing mechanical parameters determined from Chapter 3 to be important 
for predicting the deliverability of a radiotherapy treatment plan. This was accomplished 
through utilization of the machine learning algorithm described in Chapter 3 to predict 
the QA outcomes based on complexity features of VMAT treatment plans. 
The proposed algorithm – existing independently from a commercial TPS – takes 
an existing VMAT treatment plan file as input with an initial predicted GPR, and returns 
a modified version of the original VMAT treatment plan with mechanical parameters 
adjusted to result in an increased predicted GPR (see Figure 4.1). Before this QA 
optimization, the initial predicted GPR is computed for the original plan file by the 
previously mentioned machine learning model. This initial prediction serves as a 
reference point for the performance of subsequent plan modifications relative to 
changes in predicted QA outcome. After this initial QA outcome prediction, the algorithm 
selects specific features of the plan that the machine learning model deems to be the 
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most important or influential to plan deliverability. These selected plan features are then 
modified, using logic informed by the feature analysis results detailed in Chapter 3.3.1, 
before the machine learning model assesses the new predicted QA outcome as a result 
of the modifications to the mechanical parameters. This process is iterated over a given 
number of optimization iterations, after which the algorithm returns the plan file with the 
best predicted QA outcome. 
 
Figure 4.1. Conceptual overview of the proposed QA-based treatment planning 
optimization technique. First, an inversely optimized plan is taken as input with an initial 
predicted GPR. Then mechanical features identified by our machine learning model are 
randomly displaced in order to produce a new GPR prediction. This process is iterated 
to produce the largest positive GPR change. 
Initial
Plan
Novel machine 
learning-based 
optimization
Predicted GPR:
89%
QA-optimized
Plan
New Predicted GPR:
91%
SVM 
Model
Plan Complexity
GPRs
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More specifically, the algorithm was designed using the Python programming 
language. Given an initial DICOM RT-Plan file of a VMAT treatment plan, the algorithm 
begins by extracting the necessary complexity features (see Chapter 3.2.1.1 and Table 
3.1) as required by the machine learning algorithm to predict the QA outcome of the 
original plan. The machine learning model implemented in Chapter 3 was a support 
vector machine (SVM), developed on a training and testing set of 400 and 100 previous 
VMAT treatment plans, respectively. The SVM model was designed to use an array of 
plan complexity features to predict GPRs of a given VMAT plan using 3%/3mm percent 
dose-difference and distance-to-agreement gamma criteria with local normalization. The 
100 most important complexity features were selected using linear regression tests out 
of a total of 241 raw plan features, belonging to 23 general plan parameter categories 
(Table 3.1). As mentioned in Chapter 3.3.1, the feature category selected as the most 
important feature group for accurately predicting GPRs was the small aperture score, or 
SAS, for all three selection methods. Further, the five most important features selected 
according to the linear regression method were all based on the SAS, defined as the 
fraction of open MLC leaf gaps less than a given distance. As a result, although features 
were found to be weakly correlated with GPRs, the SAS feature at 50 mm had the 
strongest correlation with GPR (Figure 3.2). The model hyperparameters – including the 
kernel function, associated kernel hyperparameters, and f – were tuned via a 5-fold 
cross-validated randomized search over 250 iterations (Table 3.2). This SVM model, 
which was the best performing model out of those surveyed in Chapter 3, achieved a 5-
fold cross-validated testing mean absolute accuracy of 3.75 ± 0.29% (mean ± standard 
deviation). 
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After the GPR of the initial VMAT plan was predicted using the SVM model, the 
algorithm selected every open LG less than 50 mm over all control points in every beam 
within the plan file, as these features were previously determined to be most important 
for predicting GPRs. Then, each LG was widened by a random amount sampled from a 
uniform distribution between 0 and a maximum distance specified by the user. 
Randomized MLC leaf displacements were selected for investigation because their 
impact on the resulting calculated dose distribution is smaller compared to systematic 
leaf displacements.159 In order to avoid having the resulting changes in MLC leaf 
positions violate the minimum MU per leaf travel distance machine constraint, the 
algorithm also increased the segment weight so that the minimum MU per leaf travel 
distance never fell below 0.25 MU/cm. The modified MLC leaf positions and segment 
MUs were then saved, with which new complexity features were computed and input to 
the SVM model for evaluating the modified plan’s new predicted GPR. The modified 
MLC positions, segment MUs, and predicted GPRs were recorded after each 
optimization round. This process would be repeated for a given number of iterations set 
by the user, after which the algorithm would return a DICOM RT-Plan file with the MLC 
positions and segment MUs that yielded the highest predicted GPR. Since this QA-
based optimization occurred external to a commercial TPS, changes in the resulting 
dose distribution of these QA-optimized plans were unable to be assessed until re-
importing the plan and computing the dose. As mentioned previously however, small 
random MLC leaf displacements were utilized specifically to minimize meaningful 
changes to the subsequent dose distribution. 
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4.2.2. Feasibility Assessment 
The feasibility of this in-house, QA-based optimization algorithm was evaluated 
on a set of 13 treatment plans of previously treated prostate patients. Each plan was 
designed with two co-planar 6 MV VMAT arcs with the guidance from a previously 
established in-house KBP system.103,125,160 This KBP implementation predicts the lowest 
achievable bladder and rectum dose-volumes for new patients among anatomically 
similar previous patients available in a database, which has been shown to lead to 
significant reductions in the mean dose to the bladder and rectum compared to 
reference clinical plans while maintaining clinically acceptable dose to the target.103,125 
However, significant increases in complexity and diminished QA outcomes were also 
observed for these plans.160 Therefore, plans designed with this KBP method were 
selected for this study to assess the extent to which their predicted deliverability could 
be improved via this algorithm without compromising their dosimetric quality. 
The DICOM RT-Plan file for each of the 13 KBP plans were exported from a 
commercially available TPS. Each plan was modified with the previously described QA-
based optimization algorithm (see Chapter 4.2.1) with varying maximum LG 
displacement and number of iteration settings. Specifically, maximum LG displacements 
of 1, 3, and 5 mm were used with both 25 and 1000 optimization iterations. This 
resulted in a total of 6 QA-optimized DICOM RT-Plan files for each patient. In order to 
assess the dosimetric changes resulting from these mechanical parameter 
modifications, each DICOM file was then imported back into the same TPS in which the 
original KBP plan was designed. Then, the same dose grid settings (i.e. 4 mm/voxel 
resolution and grid coordinates) from the original KBP plan were applied to each QA-
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optimized plan before the dose was recomputed. Dose distributions of all plans for each 
patient were scaled so that 95% of the PTV received the full prescribed dose. 
Differences in predicted GPRs, plan complexity metrics, dose, and 
radiobiological metrics were assessed as a function of maximum LG displacement and 
number of optimization iterations. The specific plan complexity metrics that were 
investigated in this study were: MU factor, defined as the total planned monitor units 
normalized by the fractional prescription dose; modulation complexity score (MCS), a 
metric introduced by McNiven et al. for fixed-gantry IMRT and later adapted for VMAT 
by Masi et al. quantifies aperture area variability and leaf sequence variability into a 
composite value;113,120 edge metric (EM), a parameter introduced by Younge et al. that 
measures the “edge” in a plan through the ratio of MLC leaf side lengths over aperture 
areas;112 mean leaf motion (LM), defined as the average distance an MLC leaf travels 
per degree of gantry rotation in mm/deg; mean LG in mm; mean aperture area in mm2; 
and the small aperture score at 50 mm. 
The radiobiological metrics used in this study were equivalent uniform dose 
(EUD), tumor control probability (TCP) and normal tissue complication probability 
(NTCP).161 EUD has been described by Wu et al. as the biologically equivalent dose 
from a uniform distribution that would result in the same cell kill in the volume as the 
given non-uniform dose distribution.162 Differing from this linear-quadratic cell survival 
model, Niemierko introduced a phenomenological model of EUD defined as 
 uv: = w^_x6uy:&!<`67/ z
/<
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that can be used for both tumors and normal tissues, where { is a unitless model 
parameter that is specific to the normal structure or tumor of interest, and x6 is unitless 
and represents the |‘th partial volume receiving the biologically equivalent physical dose 
of 2 Gy, uy:&!.161,163 Specifically, uy:&! is defined as 
 uy:&! = :6 × }d ~ + :6 q; Ä}d ~ + 2Ä   
where q; and -; = :6 q;  are the number of fractions and dose per fraction size of the 
treatment course that the |‘th partial volume receives, respectively. d ~  is the tissue-
specific linear-quadratic parameter of the organ being exposed.164 A parametrization of 
the dose-response characteristics of tissues was proposed to calculate EUD-based 
TCP and NTCP, where TCP is calculated according to 
 /ÇÉ = 11 + }/Ç:@.uv: ÄAB"#  
The /Ç:@. is the tumor dose needed to control 50% of the tumor assuming a 
homogenous irradiation, and ;@. is a unitless model parameter that is specific to the 
normal structure or tumor of interest and characterizes the dose-response curve. 
Similarly, NTCP is computed according to 
 Ñ/ÇÉ = 11 + }/:@.uv:ÄAB"#  
where /:@. is the tolerance dose for a 50% complication rate at a specific time interval 
(typically taken to be 5 years in normal tissue tolerance studies) when the whole organ 
is irradiated homogenously. 
 76 
TCP for the prostate and NTCPs for the bladder, rectum, and femoral heads 
were computed for all plans for each patient. Model parameters used in this study were 
taken from previous literature and are given in Table 4.1.164 
Table 4.1. Tissue-specific model parameters used to compute EUD-based TCP and 
NTCP.164 
Tissue { ;@. /Ç:@. (Gy) /:@. (Gy) d ~  (Gy) 
Prostate -10 1 28.34 NA 1.2 
Bladder 2 4 NA 80 8.0 
Rectum 8.33 4 NA 80 3.9 
Femur 4 4 NA 65 0.85 
Differences in these deliverability (i.e. predicted GPRs) and dosimetric 
characteristics of the QA-optimized plans relative to the original KBP plans were 
statistically compared using a two-sided Wilcoxon signed-rank test with a significance 
level set to 0.05. 
4.3. RESULTS 
4.3.1. Changes in Predicted QA Outcomes 
The predicted GPRs of plans optimized with 25 iterations increased by an 
average of 0.30 ± 1.22% (p = 0.42), 1.14 ± 1.25% (p = 0.006), and 1.52 ± 1.27% (p = 
0.003) compared to the original plan when using maximum random LG displacements 
of 1, 3, and 5 mm respectively. Using 1000 optimization iterations, the predicted GPRs 
of the optimized plans increased by an average of 0.32 ± 1.17% (p = 0.31), 1.18 ± 
0.99% (p = 0.004), and 1.57 ± 1.08% (p = 0.002) compared to the original plans when 
using maximum random LG displacements of 1, 3, and 5 mm, respectively. There were 
no significant differences in predicted GPRs of QA-optimized plans when using 25 
iterations versus using 1000 iterations for each of the three displacement settings (p = 
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0.92, p = 0.35, and p = 0.92 for 1, 3, and 5 mm respectively). Figure 4.2 and Figure 4.3 
show changes in predicted GPRs for each patient using different maximum LG 
displacements at 25 and 1000 optimization iterations, respectively. The optimization 
algorithm runtime was about two minutes using 25 iterations for a given plan and 
optimization settings, whereas 1000 iterations resulted in a runtime of about 52 minutes. 
 
Figure 4.2. Changes in predicted GPRs of QA-optimized plans for each patient relative 
to the original KBP plans using maximum random LG displacements of 1 (blue), 3 
(orange), and 5 (green) mm with 25 optimization iterations. A positive value indicates 
the QA-optimized plan has the higher predicted GPR. Note these GPRs were calculated 
with a 3%/3mm percent dose-difference/distance-to-agreement gamma criterion using 
local normalization. 
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Figure 4.3. Changes in predicted GPRs of QA-optimized plans for each patient relative 
to the original KBP plans using maximum random LG displacements of 1 (blue), 3 
(orange), and 5 (green) mm with 1000 optimization iterations. A positive value indicates 
the QA-optimized plan has the higher predicted GPR. Note these GPRs were calculated 
with a 3%/3mm percent dose-difference/distance-to-agreement gamma criterion using 
local normalization. 
4.3.1.1. Changes in Plan Complexity 
Table 4.2 and Table 4.3 show changes in complexity metrics between the QA-
optimized plans and the original KBP plans overall all patients when using 25 and 1000 
optimization iterations respectively. Overall, the QA-optimized plans showed 
significantly (p < 0.05) reduced levels of plan complexity compared to the original plans, 
with the magnitude increasing with maximum random LG displacement. 
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Table 4.2. Mean ± standard deviations (µ ± !) of the differences in complexity metrics 
between QA-optimized KBP plans and the corresponding original KBP plan for 1, 3, and 
5 mm maximum random LG displacements. The QA-optimized plans were generated 
after 25 iterations. 
Complexity Metric 
KBP-QA – KBP 
(µ ± !) 
1 mm 3 mm 5 mm 
MU Factor -2.92 ± 1.04* -7.93 ± 3.27* -13.01 ± 5.28* 
MCS 0.0034 ± 0.0004* 0.010 ± 0.002* 0.015 ± 0.003* 
EM -0.001 ± 0.0001* -0.002 ± 0.0004* -0.004 ± 0.001* 
Mean LM (mm/deg) -0.001 ± 0.002 0.008 ± 0.007* 0.025 ± 0.013* 
Mean LG (mm) 0.39 ± 0.02* 1.18 ± 0.07* 1.97 ± 0.12* 
Mean Aperture Area 
(mm2) 41.80 ± 11.09* 125.61 ± 33.87* 209.30 ± 54.12* 
SAS – 50 mm -0.005 ± 0.002* -0.018 ±0.006* -0.029 ± 0.005* 
*indicates a statistically significant result with p < 0.05 
The optimization algorithm reduced MU factors by 2.92 ± 1.04 (µ ± !; p = 0.001) 
and increased the mean LG by 0.39 ± 0.02 mm (p = 0.001) using a maximum LG 
displacement of 1 mm. Aperture areas of the QA-optimized plans also increased 
significantly, where a 1 mm maximum LG displacement setting resulted in increasing 
mean aperture areas by 41.80 ± 11.09 mm2 (p = 0.001) compared to the original plan. 
Differences in complexity metrics were negligible when comparing plans using 25 and 
1000 optimization iterations. 
Table 4.3. Mean ± standard deviations (µ ± !) of the differences in complexity metrics 
between QA-optimized KBP plans and the corresponding original KBP plan for 1, 3, and 
5 mm maximum random LG displacements. The QA-optimized plans were generated 
after 1000 iterations. 
Complexity Metric 
KBP-QA – KBP 
(µ ± !) 
1 mm 3 mm 5 mm 
MU Factor -2.93 ± 1.00* -8.07 ± 3.29* -12.92 ± 5.66* 
MCS 0.0034 ± 0.0004* 0.010 ± 0.002* 0.015 ± 0.003* 
EM -0.001 ± 0.0001* -0.003 ± 0.0004* -0.004 ± 0.001* 
Mean LM (mm/deg) -0.001 ± 0.002* 0.008 ± 0.006* 0.026 ± 0.014* 
Mean LG (mm) 0.40 ± 0.02* 1.18 ± 0.07* 1.97 ± 0.13* 
    (table cont’d) 
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Complexity Metric 
KBP-QA – KBP 
(µ ± !) 
1 mm 3 mm 5 mm 
Mean Aperture Area 
(mm2) 42.12 ± 10.82* 125.42 ± 32.82* 208.99 ± 55.42* 
SAS – 50 mm -0.005 ± 0.002* -0.017 ± 0.004* -0.028 ± 0.007* 
*indicates a statistically significant result with p < 0.05 
4.3.2. Changes in Plan Quality 
Figure 4.4 shows the average of the 13 DVHs across the original KBP plan and 
the QA-optimized plans with the three different maximum random LG displacements 
using 25 iterations. Table 4.4 shows the resulting differences among selected dose 
metrics between the QA-optimized plans and the original KBP plan. Deviations in dose 
from the original plan generally increased with maximum LG displacement. While 
statistical significances were observed for most of the dose metrics for the target and 
each of the OARs, the magnitude of the differences were relatively small. For the PTV 
dose coverage, significant (p < 0.05) increases were observed for Dmin and Dmean for 
each maximum LG displacement. However, the largest average increase that was 
observed was minimal, on the order of 1.09 Gy and 0.27 Gy for Dmin and Dmean 
respectively when the maximum LG displacement was set at 5 mm. The target dose 
distributions also became slightly less conformal and less homogenous as the 
maximum LG displacement increased compared to the original KBP plan, where the 
conformity index and homogeneity index significantly increased by an average of 0.044 
and 0.009, respectively, with the maximum LG displacement set to 5 mm. 
 81 
 
Figure 4.4. Average dose volume histograms over the 13 patients comparing the 
original plan (solid black) with the QA-optimized plans using maximum random LG 
displacements of 1 (dashed red), 3 (dashdot blue), and 5 (dotted green) mm. These 
QA-optimized plans were generated after 25 iterations. 
Statistically significant increases in bladder and rectum doses were observed for 
each of the dose metrics assessed via Table 4.4. However, the largest average 
magnitude of increased Dmean to the bladder and the rectum across all possible 
maximum LG displacements was 0.83 Gy and 1.22 Gy, respectively, which correspond 
to increases of 3.06% and 4.08% of Dmean. Significant increases in Dmean were also 
observed for the left and right femoral heads and penile bulb, with the largest observed 
increases being 0.53 Gy, 0.44 Gy and 2.29 Gy on average (representing 2.04%, 1.69%, 
and 7.79% of average Dmean values), respectively. 
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Table 4.4. Average differences in dose metrics between QA-optimized plans (KBP-QA) 
and the original KBP plans for maximum random LG displacements of 1, 3, and 5 mm. 
The QA-optimized dose values resulted from plans were generated after 25 iterations. 
Dose Metric Mean (KBP-QA – KBP) 1mm 3mm 5mm 
PTV   
D2 (cGy) 3.50 32.16* 79.80* 
D50 (cGy) 4.77* 8.94 21.93* 
D98 (cGy) 0.21 3.90 6.36 
Dmin (cGy) 22.89* 65.80* 109.63* 
Dmean (cGy) 4.02* 10.97* 26.97* 
Dmax (cGy) -9.12 19.34 87.06* 
V95 (%) 0.008 0.04* 0.08* 
V98 (%) -0.01 0.02 0.06 
V100 (%) -0.12 -0.12 -0.12 
V107 (%) 0.008 0.12 0.59 
HI† 0.0004 0.004* 0.009* 
CI† 0.008* 0.025* 0.044* 
Bladder    
D10 (cGy) 23.72* 74.63* 129.33* 
D30 (cGy) 32.68* 85.22* 147.22* 
D50 (cGy) 26.89* 75.44* 123.43* 
D65 (cGy) 19.74* 45.56* 76.12* 
D80 (cGy) 10.92* 25.78* 41.83* 
Dmean (cGy) 18.94* 49.51* 82.78* 
Rectum    
D10 (cGy) 27.77* 84.26* 140.87* 
D30 (cGy) 46.57* 137.14* 226.39* 
D50 (cGy) 35.31* 98.69* 158.54* 
D65 (cGy) 25.26* 61.61* 102.77* 
D80 (cGy) 15.99* 38.91* 62.22* 
Dmean (cGy) 25.78* 72.86* 122.35* 
Left Femoral 
Head  
 
D2 (cGy) 7.26 46.19* 84.64* 
Dmax (cGy) 7.82 38.70* 80.30* 
Dmean (cGy) 6.22* 30.25* 53.10* 
Right Femoral 
Head  
 
D2 (cGy) -1.05 23.53* 47.14* 
Dmax (cGy) -1.79 27.52* 52.74* 
Dmean (cGy) 0.82 23.20* 43.89* 
    
    
    
    (table cont’d) 
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Dose Metric Mean (KBP-QA – KBP) 1mm 3mm 5mm 
Penile Bulb   
Dmean (cGy) 41.36* 133.93* 229.14* 
*indicates a statistically significant result with p < 0.05 
†Homogeneity and conformity indices were calculated according to their International 
Commission on Radiation Units & Measurements definitions. 
The changes in dose observed in Figure 4.4 and Table 4.4 for QA-optimized 
plans with 25 iterations were similar to the dose differences observed for QA-optimized 
plans resulting from 1000 iterations, as can be seen in Figure 4.5 and Table 4.5.  
 
Figure 4.5. Average dose volume histograms over the 13 patients comparing the 
original plan (solid black) with the QA-optimized plans using maximum random LG 
displacements of 1 (dashed red), 3 (dashdot blue), and 5 (dotted green) mm. These 
QA-optimized plans were generated after 1000 iterations. 
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Again, small, but significant dose differences were observed with increased 
maximum LG displacement for these QA-optimized plans resulting from 1000 iterations. 
These changes were not noticeably different from those exhibited from the QA-
optimized plans resulting from 25 iterations. 
Table 4.5. Average differences in dose metrics between QA-optimized plans (KBP-QA) 
and the original KBP plans for maximum random LG displacements of 1, 3, and 5 mm. 
The QA-optimized dose values resulted from plans were generated after 1000 
iterations. 
Dose Metric Mean (KBP-QA – KBP) 1mm 3mm 5mm 
PTV   
D2 (cGy) 3.21 28.91* 81.46* 
D50 (cGy) 4.10* 8.33 22.03* 
D98 (cGy) -0.11 1.72 3.78 
Dmin (cGy) 21.94* 67.53* 115.99* 
Dmean (cGy) 3.47* 9.79 26.82* 
Dmax (cGy) -11.14 21.46 79.98* 
V95 (%) 0.008 0.04* 0.07* 
V98 (%) -0.015 -0.006 0.07 
V100 (%) -0.12 -0.12 -0.12 
V107 (%) 0.003 0.09 0.70 
HI† 0.0004 0.003* 0.010* 
CI† 0.007* 0.025* 0.045* 
Bladder    
D10 (cGy) 24.41* 72.70* 131.35* 
D30 (cGy) 32.81* 87.39* 142.09* 
D50 (cGy) 25.45* 72.33* 129.82* 
D65 (cGy) 19.90* 46.69* 75.37* 
D80 (cGy) 11.00* 25.05* 41.95* 
Dmean (cGy) 18.80* 49.14* 82.92* 
Rectum    
D10 (cGy) 25.83* 84.41* 138.40* 
D30 (cGy) 48.10* 132.83* 231.93* 
D50 (cGy) 35.26* 98.53* 166.56* 
D65 (cGy) 24.50* 61.43* 101.76* 
D80 (cGy) 15.41* 37.45* 63.32* 
Dmean (cGy) 25.91* 72.03* 123.69* 
    
    
    
(table cont’d) 
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Dose Metric Mean (KBP-QA – KBP) 1mm 3mm 5mm 
Left Femoral 
Head  
 
D2 (cGy) 8.73* 44.04* 83.00* 
Dmax (cGy) 7.33 51.57* 84.15* 
Dmean (cGy) 6.30* 30.53* 57.11* 
Right Femoral 
Head  
 
D2 (cGy) -1.44 22.26* 49.77* 
Dmax (cGy) 0.12 23.49 64.87* 
Dmean (cGy) 0.53 22.10* 45.31* 
Penile Bulb   
Dmean (cGy) 43.38* 132.55* 224.14* 
*indicates a statistically significant result with p < 0.05 
†Homogeneity and conformity indices were calculated according to their International 
Commission on Radiation Units & Measurements definitions. 
Changes in the EUD-based radiobiological metrics TCP and NTCP can be found 
in Table 4.6 and Table 4.7 for QA-optimized plans generated after 25 iterations and 
1000 iterations, respectively. Significant increases in TCP were observed across each 
maximum LG displacement setting. Statistically significant increases in NTCP were 
observed for the bladder, rectum, and femoral heads, although the magnitudes of each 
were less than 0.22%, on average. 
Table 4.6. Summary of mean differences (∆) in the radiobiological metrics based on 
equivalent uniform doses: tumor control probability (TCP) and normal tissue 
complication probability (NTCP). Here, ∆ reflects the difference between the QA-
optimized values and the original values. Specifically, a positive ∆TCP (or ∆NTCP) 
indicates the QA-optimized plan had a higher TCP (or NTCP) value than the original 
plan. These QA-optimized plans were generated after 25 iterations. 
Max LG 
Displacement 
(mm) 
∆TCP (%) 
(10-2) 
∆NTCP (%) 
Bladder 
(10-4) 
Rectum 
(10-1) 
Left Femur 
(10-7) 
Right Femur 
(10-8) 
1 0.6* 2.2* 0.2 0.1 -0.5 
3 2.4* 4.2* 1.1* 0.7* 2.1* 
5 4.7* 8.0* 2.2* 1.3* 5.6* 
*indicates a statistically significant result with p < 0.05 
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The magnitudes in the changes observed for these radiobiological metrics were 
similar regardless of the number of iterations used to generate the QA-optimized plans. 
Table 4.7. Summary of differences (∆) in the radiobiological metrics based on equivalent 
uniform doses: tumor control probability (TCP) and normal tissue complication 
probability (NTCP). Here, ∆ reflects the difference between the QA-optimized values 
and the original values. Specifically, a positive ∆TCP (or ∆NTCP) indicates the QA-
optimized plan had a higher TCP (or NTCP) value than the original plan. These QA-
optimized plans were generated after 1000 iterations. 
Max LG 
Displacement 
(mm) 
∆TCP (%) 
(10-2) 
∆NTCP (%) 
Bladder 
(10-4) 
Rectum 
(10-1) 
Left Femur 
(10-7) 
Right Femur 
(10-8) 
1 0.6* 2.0* 0.2 0.1 0.5 
3 2.1* 4.6* 1.1* 0.7* 2.3* 
5 5.1* 7.9* 2.2* 1.5* 5.9* 
*indicates a statistically significant result with p < 0.05 
4.4. DISCUSSION 
This study explored the idea of integrating the prediction of VMAT QA outcomes 
into the plan design stage by using a machine learning model as a feedback 
mechanism within a heuristic algorithm for adjusting mechanical parameters of 
treatment plans towards increasing their predicted deliverability without degrading their 
dosimetric quality. Specifically, an SVM model based on QA measurements of 500 
previous VMAT treatment plans was implemented into the plan optimization workflow. 
The algorithm selects plan features (deemed to be important for accurately predicting 
QA outcomes using the SVM model) and randomly modifies them in searching for a 
solution that maximally increases predicted deliverability. Using 13 previous KBP-
guided VMAT plans for purposes of demonstrating feasibility, the QA-optimization 
algorithm was found to yield statistically significant increases in predicted GPRs and 
reductions in plan complexity, while minimally altering the plan quality in terms of 
dosimetric and radiobiological metrics. Although the magnitude of each of these 
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changes increased with maximum random LG displacement, a 3 mm maximum 
displacement and 25 iterations yielded QA-optimized plans with a 1.14 ± 1.25% (µ ± !; 
p = 0.006) increase in predicted GPRs and negligible increases (largest average 
increase of 0.1% among bladder, rectum, and femoral heads) in OAR NTCPs, although 
these increases were statistically significant (p < 0.05).  
To our knowledge, this is the first study exploring the feasibility of a planning and 
quality assurance framework that directly integrates predicted QA outcomes into the 
plan design process. Previous investigators have researched the efficacy of using 
individual complexity penalties to improve the deliverability of treatment plans. For 
instance, Younge et al. found it was possible to improve dose delivery accuracy by 
penalizing plans with complex aperture shapes via their “edge” metric without resulting 
in substantial changes to the dose distribution quality.112 While many different 
complexity metrics and mechanical plan features have been studied for quantifying and 
predicting pre-treatment QA results, few significant relationships have been found 
between them for VMAT QA.144,165 In other words, penalizing plan complexity without 
direct knowledge of how the associated changes in mechanical plan parameters impact 
resulting QA measurements is not guaranteed to result in improved dose delivery 
accuracy. This has led to assessing the capability of machine learning models of 
accurately predicting QA outcomes from a large array of different plan complexity 
metrics.95-97,99,101,122,166 The present work advances and builds upon these previous 
works by employing one such machine learning model for purposes of developing a 
planning QA tool for improving predicted delivery accuracy as defined by GPRs from 
QA measurements. 
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The novel and innovative component of this study is the implementation of such 
a machine learning model directly into the planning optimization process, in effect 
including predicted QA outcomes as an additional, plan-specific objective function. QA-
based optimization has the potential to improve overall plan quality without 
compromising the deliverability of the plan, in addition to producing efficiency gains in 
the treatment planning optimization and QA process. As opposed to previous studies 
that apply penalties based on single complexity or plan features, QA-based optimization 
modifies a group of aperture-based complexity metrics selected specifically to improve 
predicted GPRs. This inserts QA-specific endpoints into the plan optimization process, 
thereby providing a priori information to the planner regarding a plan’s likely QA 
outcome. Also, given the recent recommendations by TG-218 of stricter tolerance and 
action levels in evaluating patient-specific QA, QA-based optimization could help 
maintain the dosimetric quality of treatment plans while still meeting these QA 
guidelines.114 In a more general sense, QA-based optimization represents a step 
towards creating the best possible plan and delivery for each patient. 
It is important to note the limitations of utilizing radiobiological metrics for 
purposes of predicting clinical outcomes. While the goal for every radiation therapy 
treatment is to simultaneously maximize tumor cell death and minimize risk of normal 
tissue complications, treatment plans are typically evaluated by physical dose-volume 
metrics, which are merely a surrogate for these biological endpoints. This has led to an 
effort to integrate biologically relevant metrics into the treatment planning design and 
evaluation process.167,168 Even though several commercial TPSs have begun to 
incorporate biologically based models, predictive NTCP and TCP models have had 
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limited clinical presence to date due to questions of reliability and uncertainties. 
Specifically, variations in model parameter estimates (e.g. {, d ~ , etc.) have been 
shown to yield different radiobiological predictions.169-171 These uncertainties are largely 
due to a lack of satisfactory datasets for confidently establishing the correlation between 
these predictive biological metrics and realized clinical outcomes.172 Acknowledging 
these deficiencies in using NTCP and TCP models for accurately predicting absolute 
biological metrics for plan evaluation, these models’ ability to correctly capture volume 
effects and general radiobiological trends can still prove useful for a relative comparison 
in plan quality. This serves as the rationale for implementing the phenomenological, 
EUD-based models of NTCP and TCP in this study for evaluating differences in plan 
quality between QA-optimized plans and their original counterparts. Further, while 
statistically significant differences were observed in TCP and several OAR NTCP values 
among QA-optimized plans, the magnitude of these differences (maximum difference of 
0.22%; Table 4.6 and Table 4.7) can be considered small within the context of the 
uncertainties associated with these radiobiological models in general. 
This study had other limitations. One practical limitation was the inability to 
integrate QA-based optimization directly into an existing TPS optimization and dose 
calculation framework. Several options were explored and considered before deciding 
to evaluate feasibility via the present workflow. Integration of QA-based optimization 
within an existing TPS would facilitate a more efficient and comprehensive investigation 
into the tradeoff between increased levels of predicted QA outcomes and corresponding 
changes in dosimetric plan quality. This would enable a future study with a larger cohort 
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of initial testing plans as well. Nonetheless, the present results demonstrate the viability 
of implementing a QA-based optimization into an existing inverse planning workflow. 
The results from this work show that in general, predicted GPRs increased with 
larger maximum LG displacement settings. This validates the previous feature analysis 
study indicating LGs and small apertures as reasonable surrogates for adjusting the 
aperture-based complexity features used to predict GPRs by the SVM model. Further, 
larger maximum LG displacements tended to result in decreased plan complexity, but 
increased changes in dose distributions when compared to the original plans. Among 
the different magnitudes in adjustments made to the complexity features used by the 
SVM, the 3 mm LG setting seems to be a suitable selection for future integration and 
testing within a commercially available TPS as it provided the best trade-off in 
maximizing predicted GPRs and minimizing changes in dosimetric quality of the plans. 
While further investigation may reveal a more optimal maximum LG displacement 
setting, the present results suggest that the improvements in the aforementioned trade-
off would likely be clinically negligible. 
Another limitation of this study was the inherent accuracy of the machine learning 
model used to inform the heuristic search. The SVM model implemented in this work 
yielded a testing mean absolute error of 3.75% for predicting VMAT GPRs, which is on 
the order of the improvements in predicted GPRs achieved by incorporating the SVM 
model into the optimization process. However, a significant reduction in overall plan 
complexity was observed in the QA-optimized plans relative their original KBP plans 
(Table 4.2 and Table 4.3). Additionally, preliminary QA measurements of these 
optimized plans seem to agree with the differences in predicted QA yielded from the 
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SVM model, although a more thorough and complete measurement assessment is 
needed for verification. 
While this study focused on solely prostate treatment plans, it would be 
interesting to investigate the potential impact of this optimization workflow for other, 
more complex treatment sites, such as head and neck cancers. It is possible the 
differences in predicted QA outcomes would be more pronounced for treatment sites 
requiring more complex MLC leaf sequences and larger, more irregularly shaped 
apertures than prostate cases. However, given a significant increase in predicted QA 
was observed for these prostate plans without substantially degrading dosimetric quality 
provided by KBP-guidance is an indication of the potential clinical utility and applicability 
for any treatment site and inverse optimization planning environment. 
The proposed QA-based optimization framework for improving plan deliverability, 
when paired with a data-driven KBP method, represents a step forward towards a 
planning workflow integrating both dose- and QA-based objectives for designing a 
treatment plan with the best composite dosimetric quality and delivery accuracy. The 
more immediate clinical impact of this framework would be an increase in efficiency, as 
the number and likelihood of plans failing QA would decrease and could be predicted 
prior to measurement. Also, an important and novel consequence of this work is the 
ability to establish the direct connection between global plan complexity mitigation tools 
within existing TPSs and corresponding QA outcomes during the planning process. 
4.5. CONCLUSION 
While current TPSs have simple global penalties aiming to reduce complexity 
and control the likelihood of a plan failing QA measurements, these penalties are 
surrogates for QA outcomes; any potential impact on QA outcomes would be unknown 
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until measurement. This study is the first to investigate the feasibility of a planning tool 
that incorporates a machine learning model into the optimization of VMAT plans. An 
SVM model, previously trained and tested to predict VMAT GPRs based on an array of 
plan complexity features, was used to inform a heuristic algorithm for modifying plan 
parameters with the aim of increasing the predicted GPR. Significant increases in 
predicted GRPs were observed over 13 QA-optimized plans compared to original 
reference plans without substantially compromising the dosimetric quality of the plan. 
Therefore, this study has shown the feasibility of a QA-based optimization routine – with 
a maximum LG displacement of 3 mm and just 25 iterations – for increasing predicted 
plan deliverability without impacting dosimetric nor radiobiological plan quality. This 
novel QA-based optimization could be a useful addition to inverse planning workflow to 
improve both the overall quality and deliverability of clinical treatment plans. 
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5. CONCLUSIONS 
5.1. SUMMARY OF FINDINGS 
The overall goals of this dissertation were threefold: to evaluate differences in 
dose, complexity, and QA outcomes between reference clinical plans and those 
designed with an in-house KBP technique (Chapter 2); to develop and compare 
machine learning models for predicting VMAT QA outcomes based on an array of plan 
complexity features (Chapter 3); and to assess the feasibility of optimizing plan 
deliverability of VMAT treatment plans using a machine learning model to predict QA 
outcomes (Chapter 4). 
Thirty-one prostate patients previously treated with VMAT were re-planned with 
an in-house KBP method based on the overlap volume histogram. In addition to 
evaluating differences in dose, differences in VMAT plan complexity were quantified via 
normalized MUs, modulation complexity scores, the edge metric, and average leaf 
travel per degree of gantry rotation (i.e. leaf motion) for both the reference clinical plans 
and KBP plans. Each set of plans for each patient was delivered to the same diode-
array and GPRs were utilized to quantify the level of agreement between the computed 
and measured dose distributions. While KBP plans achieved noticeable gains in bladder 
and rectum dose – with average reductions of 6.4 Gy (p < 0.001) and 8.2 Gy (p < 0.001) 
in mean bladder and rectum dose compared to reference plans – they were found to be 
significantly more complex than reference plans. On average, KBP plans required 143 ± 
93 more MUs (p < 0.001), had reduced MCS values of 18% (p < 0.001; indicating 
increased complexity), had 40% higher EM values (p < 0.001), and 47% higher LM (p < 
0.001) compared to reference plans. Further, KBP plans were also more susceptible to 
QA measurement errors. For gamma criteria with global normalization, KBP plans on 
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average had gamma passing rates that were 1.1, 1.6, 3.8, and 7.8 percentage points 
lower than reference plans at the 3%/3mm (p = 0.009), 3%/2mm (p = 0.003), 2%/2mm 
(p = 0.002), and 1%/1mm (p < 0.001) criteria respectively. 
These observed differences in plan complexity and deliverability between KBP 
and reference clinical plans served as motivation for further investigating the 
relationship between complexity features and QA outcomes through the use of machine 
learning models. This was established using a dataset of 500 VMAT treatment plans 
and diode-array QA measurements, upon which an array of machine learning models 
was trained. GPRs were computed using a 3%/3mm percent dose-difference and 
distance-to-agreement gamma criterion with local normalization. 241 complexity metrics 
and plan parameters were extracted from each treatment plan and their relative 
importance for accurately predicting GPRs was assessed and compared using feature 
selection methods via forests of Extra-Trees, mutual information, and linear regression. 
Hyperparameters of different machine learning models – which included linear models, 
support vector machines (SVMs), tree-based models, and neural networks – were tuned 
using cross-validation on the training data (80%/20% training/testing split). While 
features were weakly correlated with GPRs in general, with the small aperture score 
(SAS) at 50 mm having the largest absolute Pearson correlation coefficient (0.38; p < 
0.001), the SVM model, trained using the 100 most important features selected using 
the linear regression method, yielded the lowest cross-validation testing mean absolute 
error of 3.75%. While not as accurate as previously published models designed to 
predict GPRs for fixed-gantry IMRT plans (e.g. Valdes et al. reported being able to 
predict GPRs within 3%), the SVM model in this study provided a significant 
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improvement in performance compared to “random guessing” for predicting VMAT QA. 
Furthermore, its ability to capture the general relationship between plan complexity and 
resulting QA outcomes was determined to be sufficient for utilization in the subsequent 
objective of this work: to explore the feasibility of developing a QA-based optimization 
framework for inverse planning workflows. 
A heuristic optimization framework was proposed for directly maximizing 
predicted QA outcomes of plans without degrading the quality of the plan’s dose 
distribution using the aforementioned SVM model. Thirteen of the prostate VMAT plans 
designed with an in-house KBP system from Chapter 2 were used to assess the 
feasibility of this framework. An algorithm was devised by utilizing the SVM model to 
guide iterative modification of mechanical treatment features most commonly 
associated with suboptimal GPRs. Specifically, leaf gaps (LGs) less than 5 cm were 
widened by random amounts, which impacts several complexity features such as small 
aperture scores and aperture area uniformity. The original 13 plans were optimized with 
this QA-based algorithm using maximum LG displacements of 1, 3, and 5 mm before 
corresponding changes in predicted GPRs and dose were assessed. Predicted GPRs 
increased by an average of 0.30 ± 1.22% (p = 0.42), 1.14 ± 1.25% (p = 0.006), and 1.52 
± 1.27% (p =0.003) after QA-based optimization for 1, 3, and 5 mm maximum random 
LG displacements, respectively. Differences in dose were minimal, resulting in clinically 
negligible changes in tumor control probability (maximum increase = 0.05%) and normal 
tissue complication probability (maximum decrease = 0.2% among bladder, rectum, and 
femoral heads). 
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The hypotheses of this study were (1) that KBP-guided plans would result in 
significantly higher complexity and reduced gamma passing rates (p < 0.05) compared 
to reference clinical plans and (2) that a machine learning model designed to predict 
VMAT QA gamma passing rates can be used within an in-house optimization workflow 
to increase predicted delivery accuracy without compromising KBP plan quality. To this 
end, the results of from this study support the first hypothesis as KBP plans were 
observed to have significantly increased levels of complexity and QA errors. As for the 
second hypothesis, the feasibility of using a QA-based optimization framework to 
improve predicted plan deliverability was demonstrated in this study, with improved 
levels of predicted GPRs without sacrificing the dose gains provided by the KBP 
technique. 
5.2. LIMITATIONS 
There were several limitations of this work. The use of a diode-array, while 
shown to be a viable measurement device for performing VMAT QA,140-142  lacks the 
spatial resolution advantages that can be found in other dosimeters such as film. Planar 
diode-arrays have also been shown to be overresponsive to lateral beam angles, which 
could have impacted measured GPRs in this study.139,140 A more complete 
characterization of the sources of error would be a useful future avenue of research. 
Another limitation of this study was the inability to integrate and test the QA-
based optimization concept directly within an existing TPS. This restricted the extent 
and scope of possible testing, as performing plan modifications external to a TPS before 
importing the modified plans to compute dose and evaluate changes in the resulting 
dose distribution is inefficient for testing many different patients and combinations of 
optimization settings. Still, the methods described in this work demonstrate feasibility of 
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such a method and the potential clinical advantages that warrant further TPS 
integration. 
As mentioned in Chapter 4.4, the accuracy of the SVM model used within the 
QA-based optimization algorithm was another limitation of this study. The testing MAE 
of 3.75% for predicting VMAT GPRs was larger than any of the average increases in 
predicted GPRs across the 13 patient plans that were tested via the QA-based 
optimization algorithm. However, significant reductions in overall plan complexities were 
observed for the modified plans, which aligns with what would be expected. Also, 
preliminary QA measurements of a sample of QA-optimized plans seem to support the 
predicted differences in QA outcomes from the SVM model, although a more complete 
validation study is needed. 
5.3. FUTURE WORK 
A logical next progression for this project would be to explore how these results 
generalize to other, generally more complicated treatment sites such as the head-and-
neck and to other combinations of technologies (e.g. KBP implementation, TPS, 
treatment machine, and measurement device). An important note for this study is that 
these results were observed for the specific dataset and clinical tools used in the 
experimental methods. These results, combined with those from previous works, 
indicate there may be some variation present when considering different treatment sites 
and technologies. 
It would also be worthwhile to investigate and characterize the specific sources of 
error that led to the observed decreases in KBP QA outcomes relative to the reference 
clinical plans. Although sources of error in IMRT planning and delivery have been 
studied extensively, it would be interesting to assess the primary sources of error within 
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the context of the in-house KBP method used in this study. Along the same lines, it 
would be useful to investigate a machine learning model that can predict multiple 
classes of delivery accuracy metrics that may be more clinically relevant than the GPR. 
For instance, being able to predict measured dose differences along the central axis or 
the mean gamma value, when combined with GPRs, could yield more useful indications 
for clinically relevant patient dose errors.173 
In preparation for these tools to be implemented clinically, future work would 
need to be performed to further validate the potential clinical benefits of an in-house 
KBP method and QA-based optimization framework. One or several radiation 
oncologists would need to provide feedback on the quality of the KBP-guided plans to 
ensure their clinical acceptability. Further testing of the QA-based optimization algorithm 
is also needed to verify its clinical utility, which would involve a larger number of patients 
with varying treatment sites. This testing would ideally be performed directly within an 
existing TPS. This integration with commercial TPSs represents an important and 
necessary next step towards realizing a clinically useful tool. Discussions were held with 
an interested vendor in the development of this work regarding the possibility of 
implementing and testing this QA-based optimization within their existing TPS 
framework, which did not materialize due to timeline restrictions of the project. However, 
it should be possible to integrate the present QA-based optimization framework within 
any existing TPS inverse planning process by adding a predicted GPRs objective to the 
composite objective function. This TPS integration would also facilitate further fruitful 
investigations, such as the assessment of other optimization algorithms for modifying 
the mechanical parameters that may be more efficient and lead to even larger 
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improvements in predicted GPRs. Lastly, verification measurements should be 
performed to confirm the QA predictions made by the machine learning algorithm.
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APPENDIX C. SUPPLEMENTARY MATERIAL 
C.1. CHAPTER 2 
Table C.1. Statistical summary of the differences in coefficients of variation (COV) of 
inter-delivery measurements at each gamma criteria between reference and KBP plans 
over the three separate measurements. 
 Gamma 
Criteria 
Reference Plans 
COV 
(@ ± ! x 10-2) KBP Plans COV  (@ ± ! x 10-2) t-test p-value 
G
lo
ba
l 
3%/3mm 0.3 ± 0.3 0.5 ± 0.6 0.005* 
3%/2mm 0.4 ± 0.4 0.8 ± 0.7 0.001* 
2%/2mm 0.8 ± 0.5 1.8 ± 1.4 < 0.001* 
1%/1mm 3.1 ± 2.1 4.8 ± 3.4 0.005* 
Lo
ca
l 3%/3mm 0.9 ± 0.6 1.3 ± 1.0 0.02* 
2%/2mm 1.3 ± 1.0 2.1 ± 1.6 0.004* 
1%/1mm 2.8 ± 1.9 4.2 ± 2.4 0.003* 
*Indicates a statistically significant result of p < 0.05 
 
Figure C.1. Average DVHs comparing original clinical plans (solid) to the reconstructed 
reference clinical plans (dashed) for the 31 patients of each labelled planning structure 
(a-f). The standard error of the means is also included as filled bands with solid 
(original) or dashed (reference) edge lines. Note that doses were normalized so that 
95% of the PTV received 76 Gy. 
 104 
 
Figure C.2. Distributions of the 31 paired differences between KBP and reference plans 
for planned MUs (a), MCS values (b), EM values (c), and LM (d). Positive values in 
each complexity metric plot indicate the KBP value was larger (i.e. more complex) than 
the corresponding reference plan value. Note in (b), 1 – MCS values were plotted so 
that higher values indicate higher complexity in each plot. Horizontal black lines within 
each box indicate distribution medians; notches indicate the 95% confidence intervals 
around each median, grey circles indicate the distribution means; whiskers indicate the 
range of data points lying within the 1.5 times the interquartile range and crosses 
indicate points outside this range. 
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Figure C.3. Distributions of differences in gamma passing rates between reference 
plans and KBP plans at each gamma index criteria calculated with both global (left) and 
local (right) normalization. Negative values indicate the KBP plan had a lower gamma 
passing rate. Same boxplot characteristics from the Figure C.2 caption apply here. 
 
Figure C.4. Correlation between increased plan complexity and improvement in plan 
quality. Differences between KBP and reference plans are shown, where positive y 
values indicate increased KBP plan complexity and negative x values indicate improved 
or lower bladder (a, c, e, g) or rectum dose (b, d, f, h).
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C.2. CHAPTER 3 
Table C.2. Hyperparameters of the models listed in Table 3.5 that were tuned with cross-validated searches. 
Algorithm ! " Kernel C # $ Max Depth Min Samples per Leaf Loss Number of Estimators Learning Rate Subsample 
Elastic 
Net 0.594 1 - - - - - - - - - - 
SVM - - RBF 6.407 0.094 
1&!"#$%&"' × (( - - - - - - 
Decision 
Tree - - - - - - 3 17 MAE - - - 
Random 
Forest - - - - - - 12 4 MSE 124 - - 
AdaBoost - - - - - - - - - 91 1.311 - 
Gradient 
Boosting - - - - - - 14 6  616 0.007 0.444 
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 Hyperparameter Tuning 
The following describes the specifics of the cross-validated searches carried out 
for each model to determine the optimal hyperparameters reported in the main text. 
C.2.1.1. Elastic Net 
The Elastic Net hyperparameters ! and " were optimized by a 10-fold cross 
validated grid-search over specified parameter spaces. The optimal ! was determined 
from 100 uniformly sampled values ranging from 0.005 to 0.25, while the optimal " was 
determined from 10 uniformly sampled values ranging from 0 to 1. 
C.2.1.2. Support Vector Machine 
Hyperparameters for SVMs were optimized with a 5-fold cross-validated 
randomized search with 250 iterations. Table C.3 lists the defined parameter space over 
which the randomized search was conducted. 
Table C.3. SVM parameter space ranges over which optimal parameter values were 
randomly searched with 5-fold cross-validation. 
SVM Parameter Defined Search Domain 
Kernel Linear, Polynomial, Gaussian RBF, Sigmoid 
Degree (Polynomial kernel only) 1-11 
C 1000 equally spaced points between 0.001 and 100 # 1000 equally spaced points between 0.001 and 1.5 $ (for Polynomial, Gaussian RBF, and 
Sigmoid kernels) 
1&!"#$%&"' , 1&!"#$%&"' × )( 
C.2.1.3. Decision Tree 
The Decision Tree hyperparameters optimized in this study were the maximum 
tree depth, the minimum number of samples required at each node, and the loss 
function to measure the quality of a split. These hyperparameters were tuned with a 10-
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fold cross-validated randomized search of 100 iterations over the specified parameter 
space. The range of searched values were 1 to 20 levels for the maximum tree depth 
parameter, 1 to 20 samples for the minimum number of samples required at each node 
parameter, and either MSE or mean absolute error (MAE) for the loss function. 
C.2.1.4. Random Forest 
The same tree-growing hyperparameters and their associated ranges of values 
given in C.2.1.3 were similarly optimized for Random Forests using a 10-fold cross-
validated randomized search over 100 iterations. The number of trees in each forest 
was also optimized in this randomized search, where models could have anywhere 
between 10 and 1000 estimators. 
C.2.1.5. AdaBoost 
The AdaBoost-specific hyperparameters were optimized via a 10-fold cross-
validated randomized search with 100 iterations. The parameters tuned in this study 
were the maximum number of estimators at which boosting was terminated (values 
ranged from 10 to 1000) and learning rate (values ranged from 0 to 2), which scales the 
contribution of each regressor. 
C.2.1.6. Gradient Boosting 
The optimal Gradient Boosting parameters were selected via a 10-fold cross-
validated randomized search with 100 iterations over the defined parameter space. The 
parameters tuned in this study were the maximum number of estimators (ranging from 
10 to 1000), learning rate (ranging from 10-5 to 1), the fraction of training samples to be 
used for fitting the individual base predictors (ranging from 10-5 to 1), the maximum tree 
depth (ranging from 1 to 20), and the minimum number of samples required to split an 
internal node (ranging from 1 to 20). 
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C.2.1.7.  Artificial Neural Network 
For ANN hyperparameter optimization, a randomized search of 194 iterations 
over the given parameter space (Table C.4) was performed for each of the 21 
combinations of feature sets using the open-source package Talos 
(http://github.com/autonomio/talos). Each of the 21 models was trained using 10-fold 
cross-validation. 
Table C.4. ANN hyperparameter space defined for optimization using the Talos 
package. 
Talos-specific hyperparameter Parameter space 
Learning Rate 0.001 to 1 
Number of neurons in first layer 5 to 50 
Batch Size 32 to 125 
Number of hidden layers 1 to 10 
Topology Shapes† ‘brick’, ‘triangle’, ‘funnel’ 
Epochs 50 to 500 
Dropout 0 to 0.5 
Optimizer Adam, SGD, Nadam 
Losses MSE, MAE 
Hidden layers activation function Sigmoid, tanh, relu, linear 
Output layer activation function Sigmoid, tanh, relu, linear 
†Topology shapes are package-specific names where ‘brick’ assigns the same number of neurons in each 
layer, ‘triangle’ decreases the number of neurons by a constant number with each layer so that the 
shape resembles a triangle, and ‘funnel’ decreases the number of neurons by floor of the difference 
between the specified number of neurons in the first layer and last layer divided by the number of 
desired hidden layers, resulting in a funnel shape.
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APPENDIX D. COMPLEXITY METRICS 
Below is the list of complexity features used in this work along with their 
definitions and works from which they were derived, if applicable. 
Number Name Definition Reference(s) 
1.  AA moments, weighted† 
Moments of AA weighted by CP MU 
distribution over all CPs in plan 
143 
2.  AA moments† Moments of AA distribution over all CPs in plan 
143 
3.  AA, average Average AA over all CPs in plan 143 
4.  AA, average weighted 
Average AA weighted by CP MU over 
all CPs in plan 
143 
5.  AA, weighted Sum of AAs weighted by CP MU over all CPs in plan 
143 
6.  AP moments, weighted† 
Moments of AP weighted by CP MU 
distribution over all CPs in plan 
143 
7.  AP moments† Moments of AP distribution over all CPs in plan 
143 
8.  AP, average Average AP over all CPs in plan 143 
9.  AP, average weighted 
Average AP weighted by CP MU over 
all CPs in plan 
143 
10.  AP, weighted Sum of APs weighted by CP MU over all CPs in plan 
143 
11.  Aperture Area (AA) Sum of AAs over all CPs in plan 
143 
12.  Aperture Perimeter (AP) Sum of APs over all CPs in plan 
143 
13.  Arc length Sum of degrees of gantry rotation in plan  
14.  Closed Leaf Score (CLS) 
Ratio of closed leaf pairs to all leaf 
pairs weighted by CP MU 
144 
15.  Collimator angle, average 
Collimator angle averaged over each 
beam 
95 
16.  Cross-Axis Score (CAS) 
Ratio of number of leaf pairs where 
one leaf crosses central axis over total 
number of in-field leaf pairs weighted 
by CP MU 
144 
17.  Edge Metric (EM) Ratio of MLC side lengths and aperture perimeter 
112 
18.  FAOC moments, weighted†* 
Moments of FAOC weighted by CP 
MU distribution over all CPs in plan 
95 
19.  FAOC moments†* Moments of FAOC distribution over all CPs in plan 
95 
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Number Name Definition Reference(s) 
20.  FAOC, average weighted* 
Average FAOC weighted by CP MU 
over all CPs 
95 
21.  
Fractional Area 
Outside of Circle 
(FAOC), average* 
Average fraction of AA outside a circle 
of radius r centered at isocenter over 
all CPs 
95 
22.  Leaf Gap (LG) Average LG of each leaf pair over all CPs in plan 
95 
23.  Leaf Motion (LM) 
Average leaf travel per degree of 
gantry rotation per leaf, averaged over 
all CPs in plan 
121 
24.  Leaf Travel (LT) Average total leaf travel per leaf 113, 121 
25.  LG moments, weighted† 
Moments of LG weighted by CP MU 
distribution over all leaf pairs in each 
CP in plan 
95 
26.  LG moments† Moments of LG distribution over all leaf pairs in each CP in plan 
95 
27.  LG, average weighted 
Average LG of each leaf pair weighted 
by CP MU over all CPs in plan 
95 
28.  LM moments, weighted† 
Moments of average LM distribution of 
leaves weighted by CP MU 
121 
29.  LM moments† Moments of average LM distribution of leaves 
121 
30.  LM, weighted LM weighted by CP MU 121 
31.  LT moments, weighted† 
Moments of total leaf travel distribution 
of leaves weighted by CP MU 
113, 121 
32.  LT moments† Moments of total leaf travel distribution of leaves 
113, 121 
33.  LT, average weighted LT weighted by CP MU 
113, 121 
34.  Machine Name of treatment machine 95 
35.  MLC – agility Binary, yes or no 95 
36.  MLC – i2 Binary, yes or no 95 
37.  
Modulation 
Complexity Score 
(MCS) 
Product of aperture area variability, 
leaf sequence variability, and control 
point (CP) weight 
120, 113 
38.  MU factor 
Total planned MUs divided by total 
fractional dose to the specification 
point i.e. iso 
143 
39.  Number of arcs  95 
40.  PI moments, weighted† 
Moments of AI weighted by CP MU 
distribution over all CPs in plan 
143 
41.  PI moments† Moments of AI distribution over all CPs in plan 
143 
42.  PI, average Average AI over all CPs in plan 143 
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Number Name Definition Reference(s) 
43.  PI, average weighted 
Average AI weighted by plan MU over 
all CPs in plan 
143 
44.  PI, weighted Sum of AI values weighted by CP MU over all CPs in plan 
143 
45.  Plan irregularity (PI) 
Computed aperture irregularity (AI) as 
non-circularity of each aperture: )*!+,∙)); 
sum of AI values over all CPs in plan 
143 
46.  Plan modulation (PM) 
Computed as the weighted sum of 
each beam’s modulation value: *+. =1 − ∑ 01"#∙))"##01"∙1())"#); where .(00.4) 
is the union area of all apertures of 
beam i 
143 
47.  Small Aperture Scores (SAS)‡ 
Ratio of leaf gaps smaller than given 
distance r weighted by CP MU 
144 
48.  SAS, maximum‡ Maximum of SAS scores over all CPs in plan 
144 
49.  Y jaw position, average Average of Y1 and Y2 positions 
95 
50.  Y1/Y2 jaw motion, average weighted 
Average Y1/Y2 jaw motion weighted 
by CP MU 
95 
51.  Y1/Y2 jaw motion, average† 
Average jaw travel per degree of 
gantry rotation of each Y1/Y2 jaw 
95 
52.  Y1/Y2 jaw position, average Averaged over all CPs 
95 
53.  Y1/Y2 jaw travel Total Y1/Y2 jaw travel over plan 95 
†the k = 2nd, 3rd, 4th, and 5th moments were used in this study 
‡distance criteria of r = 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 mm were used in this study 
*circles of radii = 25, 50, 75, 100, 125, 150, 175, and 200 mm were used in this study 
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